

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027747
Article Type:	Protocol
Date Submitted by the Author:	13-Nov-2018
Complete List of Authors:	Eckstein, Monika; UniversitätsKlinikum Heidelberg, Zietlow, Anna-Lena; UniversitätsKlinikum Heidelberg, Institute for Medical Psychology Gerchen, Martin; Central Institute for Mental Health, Department of Clinical Psychology Schmitgen, Mike; UniversitätsKlinikum Heidelberg, Department of General Psychiatry Ashcroft-Jones, Sarah; UniversitätsKlinikum Heidelberg Kirsch, Peter; Central Institute for Mental Health, Department of Clinical Psychology; Bernstein Center for Computational Neuroscience Ditzen, Beate; UniversitätsKlinikum Heidelberg, Institute of Medical Psychology
Keywords:	mother-infant bonding, maternal bonding difficulties, ventral striatum, oxytocin, functional magnetic resonance imaging (fMRI) neurofeedback, dopamine

SCHOLARONE™
Manuscripts

Eckstein et al NEMO study protocol

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

*Monika Eckstein¹, *Anna-Lena Zietlow¹, Martin Fungisai Gerchen^{2,3}, Mike Michael Schmitgen⁴, Sarah Ashcroft-Jones¹, Peter Kirsch^{2,3}, *Beate Ditzen¹

¹Institute of Medical Psychology, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

²Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.

³Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.

⁴Department of General Psychiatry, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

* contributed equally to this paper

Key words: mother-infant bonding, maternal bonding difficulties, ventral striatum, functional magnetic resonance imaging (fMRI) neurofeedback, oxytocin, dopamine

Word Count (Excluding title page, abstract, references, figures and tables): 5204

*Corresponding Authors:

Monika Eckstein, Anna-Lena Zietlow and Beate Ditzen

Institute of Medical Psychology,

Centre for Psychosocial Medicine,

Heidelberg University Hospital, Heidelberg University,

Bergheimer Str. 20,

69115 Heidelberg,

Germany

Email: monika.eckstein@med.uni-heidelberg.de

anna-lena.zietlow@med.uni-heidelberg.de

beate.ditzen@med.uni-heidelberg.de

Tel: +49 (0) 2221 56-7871

Eckstein et al NEMO study protocol

ABSTRACT:

Objectives:

Despite the challenges of motherhood, most mothers feel an immediate, strong emotional bond with their new-born. Maternal bonding is expressed in care-giving behaviours and sensitivity to the needs of the infant,[1]. On a neurobiological level, this is accompanied with the activation of the brain's reward system, specifically the striatal dopaminergic region,[2, 3]. However, approximately 10% of all mothers report difficulties to bond emotionally with their infant and display impaired reward responses to the interaction with their infant,[4] which might have long-term negative effects for the child's development,[5].

Functional Magnetic Resonance Imaging (fMRI) based Neurofeedback (NFB) is a new intervention technique with which participants gain direct feedback on their brain activity and can learn to control activation of specific areas. As previous studies suggest that activation of the striatal reward system can be regulated through fMRI-NFB,[6] we conceptualized and offer fMRI-NFB training to treat maternal bonding difficulties.

Setting:

In the planned trial, mothers will be presented pictures of their infant and real-time fMRI, peripheral measures, neural, endocrine, psychophysiological and behavioural measures will be assessed.

Participants:

Mothers with bonding difficulties (N= 68) will then be randomised to one of two double blind intervention groups at 4-6 months postpartum.

Interventions:

They will participate in three repeated neurofeedback training sessions with rtfMRI NFB training to increase activation of a) the ventral striatum or b) the anterior cingulate.

Outcome measures:

Interview data and real-time mother-infant interaction behaviour pre-, post-intervention and at follow-up will serve as clinical outcome measures.

Conclusions:

Rather than constituting a new standalone intervention, fMRI-NFB has the potential to serve as non-pharmacological and targeted treatment option to add to the current portfolio of therapeutic interventions in the field of maternal bonding in the postpartum period.

Trial registration:

The study is registered in the German Register for Clinical Trials (DRKS) DRKS00014570.

Eckstein et al NEMO study protocol

ARTICLE SUMMARY:

Strengths and Limitations of this Study:

- The proposed study design allows for the effect of real-time Functional Magnetic Imaging (rtfMRI) neurofeedback (NFB) to be understood in context and over time, establishing a novel therapy form that re-construes the mother-infant interaction as rewarding for the mother, in turn improving mother-infant bonding in real-time.
- The simultaneous investigation of two brain regions as well as the presence of a control group enables a comparative analysis of the benefits of the rtfMRI training, as well as helping to increase clarity regarding the role of differential brain regions in social reward.
- The proposed method, through its' longitudinal design with follow-up measures, will help to evidence how neurofeedback training brings about behavioural change, in turn allowing for better understanding of the potential applications, predictive neural signatures and participant criteria crucial for the success of rtfMRI.
- The proposed intervention aims to actively increase the response of the reward system in the mother. However, given the statistical co-occurrence of maternal bonding difficulties and postpartum depression and the similar pattern of muted reward responses in both instances, the explanatory power of the results may be confounded and therefore limited.
- The results of the planned study and increased understanding of the effects of the rtfMRI NFB method are highly relevant topics and hold clear potential for the treatment of postpartum illnesses and the long-term positive development of the infant.

INTRODUCTION:

The Neurobiological, Emotional and Behavioural Aspects of Maternal Bonding:

The parental bond is the first social bond that infants experience in life. Usually, it is the mother who serves as the child's immediate and most central social interaction partner. Maternal bonding is reflective of the first emotional bond that a mother gradually develops with her infant, within the first weeks postpartum, and is characterized by positive feelings, emotional warmth and affection towards the infant,[7]. In the eyes of some researchers, maternal bonding represents one of the most important psychological processes that gradually unfold after birth,[8] and is a significant and central aspect of the emerging relationship between mother and infant,[9].

The initial period after birth is also known as the "Baby-Honeymoon", a state of euphoria and happiness fuelled by the desire to constantly be near and to "fall in love" with the infant, which allows the mother to take on the challenges of the adaption to parenthood. In this way, maternal bonding also fulfils a biological function by ensuring the care for and subsequent survival of the new-born,[10]. On the behavioural level maternal bonding emerges through touch, eye-contact, use of "motherese", and the smiling at or caressing of the infant,[11]. Maternal bonding can therefore be expressed in the caregiving behaviours of the parent, in their focus on and high level of sensitivity to the needs of the infant,[1]. On the other hand, maternal bonding is also formed in the mother's emotions and thoughts about the infant and in the mental representations of motherhood that the mother holds,[12].

The strength of maternal bonding can also be demonstrated on a neurobiological level,[13]. One finding of central relevance to this topic is that mothers who report a good emotional bonding to their infant show increased reward-related activation in dopaminergic brain regions (the nucleus accumbens in the ventral striatum) in response to infant stimuli,[14]. These effects are particularly evident in the mother, in comparison to other caregivers, and have been assumed to be reinforced through the hormonal changes that accompany both birth and breast-feeding behaviours,[15, 16].

However, the bonding process is not always successful,[4, 17] and impaired maternal bonding can lead to avoidance or ambivalent emotions or behaviour in the mother. Impaired bonding can result not only in a lack of affection but also, in extreme cases, in the immediate rejection or neglect of the infant, as well as the possible presence of hostility or aggressive impulses,[8, 12]. Although postpartum bonding difficulties also occur in psychologically healthy mothers, they are observed particularly in the context of postpartum depression,[18, 19]. In a representative German sample 6.4% of psychologically healthy mothers reported difficulties in establishing emotional bonding with their infant. In depressed mothers the rate of prevalence is significantly higher at 17-29%,[20]. Furthermore, it has been shown that even subclinical depressive symptoms may negatively affect the developing bonding during the first months postpartum,[21].

Depression during the postpartum period itself is generally characterised by loss of interest or joylessness, insomnia, feelings of guilt, difficulties concentrating and, in severe cases, suicidal tendencies. Intense feelings and self-blame about being a bad mother are also often reported,[22]. On a neurobiological level, postpartum depression relates to a reduced level of reactivity in the striatal reward system, for example in the putamen,[23]. Studies show that in particular the mother-infant relationship,[24, 25], as well as the actual mother-infant interaction,[26], both short and long-term can be impaired by peri- and postpartum depression,[24, 27]. Results of a recent study suggest that the link between maternal depressive symptoms at 2 months postpartum and maternal report about interaction with the infant at 6 months was mediated by maternal feelings of attachment,[28]. The present study focuses on bonding impairments, rather than postpartum depression, although there will be inevitable co-occurrence in the participant sample.

Eckstein et al NEMO study protocol

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Research indicates that experiences and interaction in the “sensitive” postpartum period have long term consequences for the cognitive as well as socio-emotional development in children,[24, 29]. Animal studies have also demonstrated that positive caring behaviours of the mother positively influence offspring brain development and long-term stress-coping behaviours even in the next generation via epigenetic changes,[30]. Conversely, in humans, decreased maternal bonding can result in higher rates of self-directed affect regulation strategies and increased stress-reactivity [31] of the infant, as well as variable self-comfort behaviours, moderated by the infant’s gender and age,[31]. Research also indicates that restrained (distant) maternal behaviour can have far-reaching negative consequences for self-regulation, social behaviour and stress management in the infant [24, 29], even into adulthood with potential influences on own parenting behaviour,[32]. Furthermore, the association between maternal depression, anxiety disorders and stress-reactivity with changes in the hypothalamic-pituitary-adrenocortical axis (HPA axis) is well-documented,[33]. Indeed, recent studies indicate that infant exposure to maternal mental disorders can increase infant baseline cortisol levels, as the main outcome of the HPA axis, in the case of maternal depression and increase infant cortisol reactivity in cases of maternal anxiety,[34]. In a lower income setting, exposure to variable intensities of maternal depression demonstrated a U-shaped response curve in infant cortisol reactivity levels in the context of immunisation. Those with exposure to moderate-maternal depression levels demonstrated the lowest cortisol reactivity during immunisation,[35]. The importance of the influence of maternal interaction behaviours themselves is also clear. One particular study demonstrates, for example, that maternal sensitivity during the interaction with their infant has a moderating influence between maternal mental health during pregnancy and infant salivary cortisol levels,[36]. Given data on the transgenerational transmission of maternal care via epigenetics,[37], both in maternal-infant bonding,[38-40] and care-giving behaviours,[41] the importance of effective treatment and intervention plans are evident.

Current inpatient and outpatient mother-infant therapies, established in the context of postpartum mental disorders, focus not only on the disorder-specific treatment but also on specific elements for the promotion of the mother-infant relationship (e.g. baby massage and video feedback methods). Video feedback interventions have been shown to have a positive influence on mother-infant interaction,[42, 43] as well as the maternal self-efficacy in interacting and coping with the infant,[44, 45]. To our knowledge, maternal bonding has thus far only been recorded as an outcome variable in one study using video feedback invention,[46]. This intervention demonstrated improvements in maternal bonding; however, the participant pool only included mentally healthy women without postpartum bonding problems. Thus, interventions focussing on maternal bonding in women experiencing difficulties forming an emotional bond to their infant are urgently needed. Presently, such interventions or findings, directly relating maternal bonding difficulties and their effects on the infant’s stress reactivity in either biological or behavioural domains, are still lacking and in particular non-pharmacological treatment concepts would substantially broaden the treatment options for affected mothers and their infants.

Reward Learning in Depression and its Relation to Postpartum Bonding Difficulties:

On a neural level the dopamine-mediated reward system (specifically the ventral striatum and the nucleus accumbens) is crucial to the rewarding aspects of social interaction,[47, 48]. The ventral striatum also appears to be specifically involved in learning rewarding stimuli, where high neural activation, correlated with the “BOLD response” in the fMRI, is accompanied by an increased dopaminergic response,[47]. As part of the learning process this reward activation is first triggered by primary enhancers, such as glucose, and over the course of the learning process transfers to secondary enhancers, such as food or money. In humans, from early in life, repeated positive social experiences can be seen as very strong reward and provided the basis for the much discussed “social brain hypothesis”, in brain research [49, 50].

Eckstein et al NEMO study protocol

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Images of happy children are generally perceived as positive by healthy individuals and activate the striatal areas of the brain,[51]. Psychologically healthy mothers also show a differential neural activation response to visual stimuli of happy children, as compared with stimuli of more ambiguous facial expressions of children. Expressions of joy activated the right limbic and paralimbic areas, by comparison ambiguous expressions correlated to activity in the left higher cognitive and motor areas that are often linked to cognitive effort,[52]. Consequently, positively reinforcing activities that lead to such activation, i.e. positive social interaction, are likely to be subsequently performed more frequently. In the case of the presence of depressive symptoms, however, such neural activation (i.e. activation in striatal and limbic networks) seems to be diminished during positive social interactions, these activities are therefore perceived as less rewarding,[53, 54] and diminish the motivation for social contact. Mothers with depressive symptoms demonstrated reduced activation in subcortical and cortical limbic regions (amygdala, cingulate) and cortical regions involved in emotion regulation (including the frontal cortex, insula, anterior cingulate); in line with symptomology of diminished capacities to experience joy and to down-regulate anger, anxiety, or worry,[23, 55, 56]. Notably mothers with postpartum depression show a reduced activation in striatal reward areas in response to stimuli of their own children,[23, 55, 56].

On a neuroendocrine level, basic research suggests that in rodents social-interaction related reward is associated with receptor-activation for the neuropeptide oxytocin in the nucleus accumbens,[57]. Initial data in humans indicates, that methylation of the oxytocin receptor gene is associated with attachment in different phases of the individual's lifespan,[58] and higher methylation is associated with postpartum depression,[59]. Antidepressant treatment, in turn, is assumed to lower methylation,[60]. This may explain, on a neurobiological level, the correlation between postpartum depression and maternal bonding difficulties,[61]. However, no contemporary intervention has yet focussed on the perception of the mother-infant interaction in terms of reward and involved oxytocin-related outcomes as possible evaluation criteria.

rtfMRI NFB as a Treatment Method:

Neurofeedback (NFB) is a novel method which, through the visualization of real-time brain activation, allows an individual to consciously regulate one's own brain activation. While it is well-established that mental strategies modulate brain activation as measured by fMRI blood oxygen level dependent signal (BOLD), NFB asks participants to modulate activation in prescribed regions of their brain by their own volition and in response to the immediate feedback/ visualization of the related brain activation patterns,[62]. Thus, volunteers can learn to regulate the activation of a previously defined brain region (see,[63] for a review). NFB interventions have previously often used electroencephalography (EEG) and other electrophysiological methods to visualize and modulate activation in higher-cortical areas. However, smaller and deeper areas of the limbic and reward system can be imaged primarily with high-resolution magnetic resonance imaging (MRI). From a therapeutic point of view, the targeted modulation of these brain areas and associated circuits via neurofeedback should be associated with the improvement of mental symptoms.

In initial pilot studies, for example, patients with borderline personality disorder, anxiety or obsessive-compulsive disorders have shown the ability to down regulate activation in the insula or the hyperactive amygdala in response to stress-related stimuli,[64-66]. Similarly, high risk alcohol consumers learned to down regulate the reward related activation of alcohol related stimuli,[6]. In PTSD patients, the changes in brain connectivity after fMRI neurofeedback correlate with the reduction of symptoms,[67]. Based on the previously articulated and evidenced notion of the psychobiological mechanisms underlying attachment and bonding as goal-oriented and reward-drive,[68], the proposed study looks to investigate whether specific activation of the ventral striatum can be voluntarily increased through training in the context of mother-infant bonding. Indeed in previous research,

Eckstein et al NEMO study protocol

patients with major depressive disorders or schizophrenia were successfully trained to increase the activation of the hypoactive amygdala and the anterior cingulum in conjunction with positive stimuli,[69, 70]. Therefore, in line with the current understanding and treatment of mental illnesses, rtfMRI NFB represents a promising new intervention method for complex mental processes. Particularly important for understanding the potential of rtfMRI interventions is the transfer of the modulation of the BOLD signal towards behavioural changes,[62] which allows the value of this intervention form in a clinical setting to be distilled.

The Planned Trial:

In the planned double-blind randomized intervention trial (the “Neurofeedback for Mothers with Postpartum Bonding Difficulties Study”, “NeMo-Study”), three central points will be addressed.

1. Women with postpartum bonding difficulties (including women with postpartum depression) will be compared to healthy unaffected women in terms of reward-related brain activation to pictures showing their own infant and control stimuli. It is hypothesized that women with bonding difficulties show less brain response in the reward-related areas (ventral striatum) compared to the control group.
2. The clinical group will then undergo a regiment of NFB training. Participants will learn to consciously increase the activation of reward-associated brain areas (specifically the ventral striatum), or a control region (anterior cingulate cortex, ACC), during the presentation of images of their own infant (as opposed to unknown pictures of babies). The activation of the central nervous dopamine system is hypothesized to improve bonding motivation and social interaction behaviour. The coupling of infant stimuli to the central nervous reward activation should make it easier for these women to feel more joy in the real interaction,[62] with their infant post-training and to be more attentive and more sensitive in their interactions. Training of the ventral/rostral ACC with a rather unspecific role in emotion regulation, such as in cognitive reappraisal,[71], may have general beneficial effects on parental affect regulation,[69] as well as in the more specific context of maternal bonding as based on the rewarding aspects of the mother-child interaction.
3. Effects of the NFB training will be related to the changes in behaviourally coded mother-infant interaction, maternal bonding quality and diagnostics, and epigenetic oxytocin receptor alterations, as assessed from peripheral blood. It is hypothesized that following the ventral striatum intervention, interaction, maternal bonding, and epigenetic markers will approximate the values of the healthy control group.

Thus, the study will address reward-related processes in impaired maternal bonding, observable changes on a behavioural and neuroendocrine level post-training - important steps in illustrating the validity of rtfMRI NFB as an intervention method,[62]. The proposed study is therefore well placed to produce a wealth of valuable and informative data, both regarding the potential scope of rtfMRI as a non-pharmacological intervention to young mothers.

Eckstein et al NEMO study protocol

METHODS AND ANALYSIS:

Design Overview:

To investigate points 1) – 3) (above) a controlled longitudinal study with randomised allocation of the two intervention groups to one of two anatomically defined regionally targeted areas in the NFB training will be employed. The two intervention groups will consist of mothers with identified maternal-bonding difficulties, while the control group will consist of psychologically-healthy mothers without bonding difficulties. The intervention groups will receive three NFB training sessions at intervals of approximately 14 days. Changes in maternal behaviours during mother-infant-interaction, measured using standardised coding of behavioural observations, will be assessed as the primary outcome measure. Possible alterations in oxytocin receptor methylation and gene expression will serve as secondary outcome measures. See Figure 1 for overview of study design and timeline (Figure 1).

[Figure 1: Overview of Study Design around here]

Eckstein et al NEMO study protocol

Participant Eligibility and Recruitment:

Eligible Participants:

Intervention Group: Mothers who report postpartum bonding difficulties, may present with a wide range of depressive symptoms.

Control Group: Psychologically healthy mothers with intact bonding to child.

Exclusion Criteria for all Groups:

Mothers: acute suicidality, bipolar or schizophrenic disorders, diagnosed dementia or substance abuse or substance dependency. Necessary fMRI exclusion criteria also apply.

Infants: multiple birth infants, preterm birth, confirmed physical or developmental disorders, which make participation impossible or unwise.

Patient and Public Involvement

Participants will be recruited both online and by flyers disseminated through midwives, gynaecologists, paediatricians, in pharmacies and in maternity hospitals as well as mothering forums or self-help groups (e.g. "Shadow and Light ") and registration offices. They receive thorough information about the study procedures both orally and in written form. The volunteer recruitment structure of the study makes it possible that given the intense feelings of self-blame symptomatic of the often co-occurring postpartum depression,[19] those most severely affected may not volunteer for the study. This limitation will be addressed via carefully worded and emphatic recruitment materials and processes.

Screening assessment and group allocation:

Screening Assessment:

For inclusion in the study all potential participants will be screened (T0) prior to inclusion.

Random Group Assignment Procedure:

True random assignment to the two clinical intervention groups or the control group cannot occur due to the quasi-experimental nature of the design: The mothers are assigned to being clinical or control based on the quality of their postpartum bonding to their infant. Inclusion as part of the clinical intervention group is based on the categorical assessment of impaired maternal bonding using an in-depth interview based on the proposed criteria by,[20] and asked during the clinical interview. This approach additionally allows for the dimensional assessment of maternal-bonding impairments. Bonding assessment is further elaborated by the use of additional questionnaires exploring bonding impairment, such as the Postpartum Bonding Questionnaire 16 (PBQ-16), which holds an internal consistency of Cronbach's $\alpha=0.085$,[11].

Within the intervention group participants will be completely randomly and automatically assigned to one of the following two conditions: NFB of the right ventral striatum (clinical intervention group I) or NFB of the right anterior cingulate cortex (ACC) (clinical intervention group II). This randomisation is based on the order of inclusion into the study and pre-assigned lists that are double-blind in nature. During all three intervention sessions, participants will be trained to modulate activation of the same pre-defined brain region (right ventral striatum or right ACC) based on the functional tasks during T1.

Power Analysis and Size Estimation:

The program G-Power v.3.1.9.2,[72] was used, in order to calculate the required sample size. To test the hypotheses mentioned above, a total of approximately N = 100 cases is estimated.

Eckstein et al NEMO study protocol

To perform a simple group comparison of maternal sensitivity between two treatment groups with a middle to large effect size ($d = 0.78$),^[43] with a power of 90% and an alpha-error threshold of $p = .05$, a minimum group size of $N = 30$ for each clinical intervention group is required (I, NFB of the ventral striatum, II, NFB of the ACC). Assuming a drop-out rate of approx. 10%, an experimental sample of $N = 100$ will be aimed for in the projected study. With a repeated measures analyses and the T3 (follow-up) measurement the power is improved, which makes it possible to observe even medium effects with this planned sample.

$N = 68$ mothers with postpartum bonding difficulties will be included in the intervention ($N = 34$ to NFB region I ventral striatum, $N = 34$ to NFB region II ACC). Mental disorders, and especially postpartum depressive symptomatology, are measured in a multi-dimensional fashion through a structured clinical interview and a validated peri-partum period questionnaire. Variability in depressive symptoms, ranging from none to moderate symptom-load is sought, thus allowing for appropriate and adequate statistical analysis of this covariate factor. As a control group $N = 32$ psychologically healthy women with a good bond with their infant will be recruited.

Pre- Post and Follow-Up Assessments (T1, T2 and T3):

Before (T1) and after the training (T2), participants will perform an extensive battery of diagnostic assessments characterizing the clinical aspects of bonding, including the instructed mother-child-interaction in the Face-To-Face-Still-Face-Paradigm,^[73, 74]. A baseline fMRI session will assess the sensitivity of both the reward system and the limbic system using established fMRI tasks and blood samples will be collected for analysing hormonal and (epi-)genetic markers. After the end of the last neurofeedback training a post-intervention measurement (T2) and with 12 month a follow up (T3) will be performed using the same methods as at T1. At T3, mothers and infants will be instructed to freely play,^[75] and videotaped. Age-specific markers of the infant's development will be coded using a standardized developmental test,^[76]. (Refer to Figure 1 for timeline clarification).

This combination of assessments allows for a comprehensive understanding of maternal bonding and behaviour on a neural, neuroendocrine, epigenetic and behavioural level.

See Table 1 for further details on the assessments and scheduling of measure collection.

Eckstein et al NEMO study protocol

Survey instruments and Coding Systems used in the Study:

Measure	Citation	M.	F.	I.	T0	T1	N	T2	T3
Mother and infant:									
Mother-Infant Interaction (FFSF)	[74, 77]	X		X		X		X	
Free-Play Situation	[75]	X		X					X
Interviews:									
Diagnostic Interview for Psychiatric Disorders	Adapted for DSM-5, unpublished manual	X							
Interview for Postpartum Bonding Disorders	[78]	X	X						
Attachment Style Interview	[79]	X	X						
Questionnaires:									
Postpartum Bonding Questionnaire 16-R	[11]	X	X			X		X	X
Edinburgh Postnatal Depression Scale	[80]	X	X			X		X	X
Agoraphobic Cognitions Questionnaire, Body Sensations Questionnaire, and Mobility Inventory	[81]	X	X			X		X	X
Maternal Self-Confidence Scale	[82]	X	X			X			X
Prenatal Emotional Stress Index	[18]	X	X						
Parental Bonding Instrument	[83]	X	X			X			
German version of the EMBU questionnaire regarding remembered parenting behaviours	[84]	X	X			X			
Experiences in Close Relationships- Revised	[85]	X	X			X			
Social Support Questionnaire	[86]	X	X			X		X	X
Personality Inventory- DSM 5 Short Form	[87]	X	X			X			
Childhood Trauma Questionnaire	[88]	X	X			X			
Partnership Questionnaire	[89]	X	X			X		X	X
Dyadic Coping Inventory	[90]					X		X	X
Parenting Stress Inventory	[91]	X	X					X	X
Vulnerable Attachment Style Questionnaire	[92]	X	X			X			
Infant:									
Infant Behaviour Questionnaire	[93]	X	X			X			X
Development Assessment: Infant									
Bayley's Infant Development Scale III	[76]			X					X
Physiological Measures									
Infant Saliva Sample				X		X		X	X
Mother Blood Sample		X				X		X	X
Neurofeedback Training									
Reward Task	[94]	X				X		X	X
Emotional Go-No-Go	[95]	X				X		X	X
Passive Viewing Task	[96]	X				X		X	X

Table 1: Schedule of measures used the in study. M. Mother Response, F. Father response, I. Infant response, T0 screening assessment, T1 baseline assessment, N-neurofeedback sessions, T2 post assessment, T3 follow-up.

Detailed Description of Measures, Methods and Instruments used:

Initial Assessments:

Baseline Assessment:

For the baseline testing period (T1) the mothers will be invited to our video-laboratory together with their infants. A structured clinical interview according to DIPS as well as an interview regarding postpartum bonding impairment will be carried out. Subsequently, parent-infant interaction will be assessed and videotaped during the Face-to-Face-Still-Face (FFSF) paradigm, a widely used paradigm for evaluating the quality of early parent-infant interaction,[73]. To determine infant stress-reactivity, cortisol and alpha-amylase will be extracted from infant saliva according to standard protocols,[97], which is collected before (C1), immediately after (C2), 20 minutes (C3) and 30 minutes after the FFSF (C4).

Instructed Mother-infant interaction:

Mother-infant-interaction pre- post-intervention (T1 and T3): The standardised mother-infant-interaction before and after the intervention follows the established FFSF paradigm,[74, 77]. It consists of three consecutive instructed two-minute episodes in which the mother, with the infant seated in the baby chair, interacts in accordance with a fixed pattern: First, an initial face-to-face interaction in which the mothers are instructed to play with their infant as usual (without the aid of toys and pacifiers). Next, the still-face episode in which the mothers have to turn their head aside while silently counting to ten and then turn back to the infant but not engage in any gestures, facial expressions, or vocalizations. Finally, the procedure ends with the reunion episode in which the mother is required to resume face-to-face play with her infant.

Mother-infant-interaction Follow-Up (T4): As the Still-face paradigm can be conducted up to the age of 9 months, parent-infant interaction will be assessed at T4 during a 15-minute free-play situation and a subsequent limit setting task. All interaction episodes will be videotaped and coded according to the Coding Infant Behaviour Scales (CIB),[98]. The CIB scales assess parental sensitivity and responsiveness as well as intrusiveness and withdrawal via composite scores,[99]).

Psychobiological Measurements:

Epigenetic Information on the Oxytocin-System and Cortisol/Alpha Amylase in Saliva:

Maternal blood samples are taken to examine the endogenous oxytocin level, gonadal hormones and epigenetic parameters of the oxytocin gene and oxytocin receptor gene. For the endocrine investigation of the stress hormone cortisol painless saliva samples are taken from the infants directly before, immediately after 20 and 30 minutes after the mother-infant interaction using a saliva probe. An elevation of infant stress-reactivity is expected during the interaction, from these elevations the Peak and Recovery be ascertained. The area under the curve is therefore analysed as a reactivity index,[100] as is standard practice,[101].

MRI-tasks:

Reward Task:

The task, (adapted from,[94]), requires participants to perform a spatial working memory task with two levels of cognitive load, differentiated by the number of circles to be remembered. Subjects first see a cue informing them of the potential monetary reward value – high or low. After presentation of the fixation cross, an array of yellow circles (3 or 7 circles), is displayed followed the target, a green circle, that is then presented at any position on the screen. The participants must decide whether this circle is in the same position as one of the circles presented previously. In the rewarded condition, a feedback about the win (followed by the cumulated amount of earned money appears. Correct responses are reinforced by two different amounts of monetary reward that are counterbalanced with the levels of cognitive

Eckstein et al NEMO study protocol

load. Incorrect responses on rewarded trials result in no monetary gain. While performing the task, participants rate their mood and stress levels a quarter of the trials.

Emotional Go/NoGo:

The participants are presented with positive and negative expressions of unknown babies, unknown adults as well as un-social control stimuli (geometric figures; a circle, a cross, a diamond and a triangle) over three presentation blocks.

The following factors are systematically manipulated: child vs adult and emotionality of facial expression (positive vs negative). In two blocks, the participants receive instructions to respond by pressing a button as fast as possible to all facial expression except the negative (one block babies, one block adults). In two other blocks they are instructed to respond as fast as possible to all except the positive (one block babies, one block adults). In the two non-social blocks the participants should react as fast as possible to all shapes but not to a circle or a diamond,[95].

Passive Viewing Task:

The participants view previously collected neutral-positive images of partners and their babies in positive and negative affect, with instructions to observe carefully. Unfamiliar men and babies will serve as control stimuli. Viewing images of partners and children leads to the activation of a broad socio-emotional neural network, that is involved with empathy and socio-emotional cognition,[23, 96].

Coding Systems Used in the Study:

Coding Interactive Behaviour:

For the evaluation of the mother-child interaction over all measurement points the Coding Interactive Behaviour System was used (CIB:[75]). The CIB is a widely used, global rating system for analysing mother-infant-interaction. The system uses multiple codes for the infants, parents and dyadic codes that aggregate into meaningful theoretically-based constructs (e.g., sensitivity, intrusiveness, reciprocity, social engagement, withdrawal). The psychometric characteristics are all well described,[102].

Infant Development Diagnostics used in the Study:

Bayley Scales of Infant and Toddler Development-III:

The Bayley Scales of Infant and Toddler Development-III (Bayley-III:[103, 104]) assess the development of infants and toddlers between one and 42 months of age. The test battery covers the domains of cognition, language, motor, social-emotional and adaptive development using I-Q-scaled composite scores. Whereas the first three aspects are assessed by behavioural observation and the latter two utilize questionnaires, with duration ranging between 50 and 90 min,[105]. The Cognitive Scale assesses sensory-motor development, exploration and manipulation, object relatedness, concept formation and memory. The Language Scale is composed of the two subscales receptive and expressive communication. Testing pre-verbal behaviour, vocabulary development, understanding of morphological markers, social referencing and verbal comprehension and pre-verbal communication, vocabulary development and morpho-syntactic development respectively. In addition, the Bayley Scales include a Gross- and Fine-Motor Scale, a Social-Emotional Scale, and an Adaptive Behaviour Scale. This study focuses on the language and cognitive composite scores due to the rather small proposed sample size.

The Bayley-III indices and subscales demonstrate good internal consistency and good split-half-consistency according to the Spearman-Brown formula,[105]. Regarding construct validity, confirmatory factor analysis of the subtests of the Cognitive, Language, and Motor scales supported a three-factor model across all ages. The Bayley-III scales have

Eckstein et al NEMO study protocol

1
2
3 been normed for German infants and children,[106]. This method is taken standard
4 internationally, particularly in terms of reviewing developmental delays and planning targeted
5 early interventions. The order of the subtests can be adapted to the needs of the child.
6

7 **Neurofeedback Setup:**

8 The mothers with bonding difficulties will be randomised to receive one of the two following
9 interventions: I) NFB for activation of the ventral striatum or II) neurofeedback for activation
10 of the anterior cingulate cortex (ACC). Participants will partake in NFB training over three
11 sessions at intervals of approximately 14 days (refer to Figure 1). At baseline, a high-
12 resolution structural MRI scan and the activation pattern based on the infant-like stimuli will
13 be recorded (using a Tim Trio 3T MRI scanner, Siemens, Erlangen, Germany).
14
15

16 Each intervention session will last approximately 60 minutes and will begin with a
17 10minute preparatory structural MRI scan. A 6minute resting state fMRI scan is then
18 conducted to allow a resting baseline to be established and to prepare the neurofeedback
19 set-up. Afterwards, three rtfMRI NFB runs of 9:29 minutes are conducted. During
20 neurofeedback training positive and neutral pictures of the participants' own child taken from
21 the recorded mother-infant interaction session will be presented together with an on-screen
22 "thermometer" which represents the current intensity of activation in the striatum or ACC and
23 must be upregulated. In each run, six alternating phases of up-regulation (~41 seconds,
24 including a ~10 second initial period without thermometer display) and of rest (observation of
25 a fixation cross, ~41 seconds) will be performed. (See Figure 2 for details). The women are
26 instructed to try several strategies and use the one that works best. Afterwards, they are
27 asked to report which strategy they used. In the first and third scanning session the third run
28 is implemented as a "transfer" block without the visible "thermometer" display,[6, 65, 70]. For
29 more technical details regarding the neurofeedback setup please refer to [107] which uses
30 an identical neurofeedback procedure in the context of alcohol addiction.
31
32
33

34 [Figure 2: Two Trials of the Neurofeedback Intervention within a Run around here]
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eckstein et al NEMO study protocol

Data Analysis Plan:

Statistical analyses, namely the main comparison of the two groups (mothers with bonding difficulties vs. the control group) and the longitudinal analysis of positive relationships changes after the NFB intervention (interaction behaviour, attachment data, as well as psychophysiological, neuroendocrine and epigenetic markers (see Table 1) will be done using IBM SPSS Statics and R (r-project.org). The MRI data will be analysed with general linear models using statistical parametric mapping with SPM (<https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) implemented (Wellcome Department of Cognitive Neurology, London, UK) in MATLAB (MathWorks, Natick, MA) MATLAB . To calculate pre-, post- and follow-up group differences between the intervention and control groups, repeated measures ANOVAs will be calculated, while multi-level models will be used to model changes over the time course.

For peer review only

Eckstein et al NEMO study protocol

Figure Legends:

Figure 1:

Overview of Study Design

Figure 2:

Two Trials of the Neurofeedback Intervention within a Run

For peer review only

Eckstein et al NEMO study protocol

ETHICS AND DISSEMINATION:

Ethics, consent to participate and Dissemination:

Study procedures are in line with the recommendations of the World Medical Association (revised Declaration of Helsinki) and were approved by the Ethics Committee of the Medical Faculty, s-450/2017, Heidelberg University. The study is registered as clinical trial in the German Register for Clinical Trials (DRKS) DRKS00014570. All participants will provide written informed consent after receiving a detailed oral and written explanation of all procedures and can withdraw their consent at any time without negative consequence.

Results will be internationally published and disseminated, to further the discussion on non-pharmacological treatment options in complex mental disorders.

Consent for Publication:

Not applicable.

Availability of Data and Material

For protection of personal rights and due to the sensitivity of the clinical information, raw data will not be available in the public domain. The medical confidentiality and the provisions of the EU-DSG (Data Protection Act) are therefore complied with; the collected medical findings and / or personal information are recorded in the examination centre or stored electronically.

Furthermore, important data for the study are stored in an anonymised format, evaluated and, if necessary, passed on to the necessary persons. Third parties gain no insight into the original data with the database remaining restricted for scientific use only. If results are published, it will not be possible to draw any conclusions to an individual as the confidentiality of personal data remains guaranteed at all time

REFERENCES:

1. Tietz, A., A.-L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. Archives of women's mental health, 2014. **17**(5): p. 433-442.
2. Strathearn, L., et al., *Adult attachment predicts maternal brain and oxytocin response to infant cues*. Neuropsychopharmacology, 2009. **34**(13): p. 2655-2666.
3. Zietlow, A.-L., M. Heinrichs, and B. Ditzen, *Psychobiologie sozialer Nähe*. PiD-Psychotherapie im Dialog, 2016. **17**(03): p. 82-84.
4. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: Psychometric properties and association with postpartum depression*. Archives of Women's Mental Health, 2006. **9**(5): p. 265-271.
5. Fuchs, A., et al., *The Early Mother-to-Child Bond and Its Unique Prospective Contribution to Child Behavior Evaluated by Mothers and Teachers*. Psychopathology, 2016. **49**(4): p. 211-216.
6. Kirsch, M., et al., *Real-time functional magnetic resonance imaging neurofeedback can reduce striatal cue-reactivity to alcohol stimuli*. Addiction biology, 2015.
7. Klaus, M., Kennell, J., & Klaus, P., *Bonding*. 1995, New York: Addison-Wesley.
8. Brockington, I., *Postpartum psychiatric disorders*. Lancet, 2004. **363**(9405): p. 303-10.
9. Klaus, M.H. and J.H. Kennell, *Parent-infant bonding*. 2. ed. ed. 1982, St. Louis, Mo [u.a.]: Mosby. XIX, 313 S.
10. Maestripieri, D., *Is There Mother–Infant Bonding in Primates?* Developmental Review, 2001. **21**(1): p. 93-120.
11. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: psychometric properties and association with postpartum depression*. Archives of women's mental health, 2006. **9**(5): p. 265-271.
12. Hornstein, C., E. Hohm, and P. Trautmann-Villalba, *Die postpartale Bindungsstörung: Eine Risikokonstellation für den Infantizid?* Forensische Psychiatrie, Psychologie, Kriminologie, 2009. **1**: p. 1-8.
13. Feldman, R., *The adaptive human parental brain: Implications for children's social development*. Trends in Neurosciences, 2015. **38**(6): p. 387-399.
14. Strathearn, L., et al., *What's in a smile? Maternal brain responses to infant facial cues*. Pediatrics, 2008. **122**(1): p. 40-51.
15. Bakermans-Kranenburg, M.J. and M.H.v. IJzendoorn, *Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting*. SCAN, 2008. **3**: p. 128-134.
16. Feldman, R., et al., *Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding*. Psychol Sci, 2007. **18**(11): p. 965-70.
17. Brockington, I., H. Aucamp, and C. Fraser, *Severe disorders of the mother–infant relationship: definitions and frequency*. Archives of women's mental health, 2006. **9**(5): p. 243-251.
18. Moehler, E., et al., *Maternal depressive symptoms in the postnatal period are associated with long-term impairment of mother-child bonding*. Archives of Women's Mental Health, 2006. **9**(5): p. 273-278.
19. Reck, C., et al., *Perceived parenting stress in the course of postpartum depression: the buffering effect of maternal bonding*. Arch Womens Ment Health, 2016. **19**(3): p. 473-82.
20. Brockington, I.F., et al., *A screening questionnaire for mother-infant bonding disorders*. Archives of Women's Mental Health, 2001. **3**(4): p. 133-140.
21. Tietz, A., A.L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. Archives of Women's Mental Health, 2014. **17**(5): p. 433-42.
22. Hofecker-Fallahpour, M. and A. Riecher-Rössler, *Depression in der frühen Mutterschaft*. Neurotransmitter Sonderheft, 2003. **2**: p. 35-39.
23. Laurent, H.K. and J.C. Ablow, *A face a mother could love: depression-related maternal neural responses to infant emotion faces*. Social neuroscience, 2013. **8**(3): p. 228-239.
24. Reck, C., N. Nonnenmacher, and A.L. Zietlow, *Intergenerational Transmission of Internalizing Behavior: The Role of Maternal Psychopathology, Child Responsiveness and Maternal Attachment Style Insecurity*. Psychopathology, 2016. **49**(4): p. 277-284.

Eckstein et al NEMO study protocol

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
25. Zietlow, A.-L., et al., *Maternal Self-confidence Postpartum and at Pre-school Age: The Role of Depression, Anxiety Disorders, Maternal Attachment Insecurity*. *Maternal and Child Health Journal*, 2014. **18**(8): p. 1873-1880.
26. Reck, C., et al., *Interactive coordination of currently depressed inpatient mothers and their infants during the postpartum period*. *Infant Mental Health Journal*, 2011. **32**(5): p. 542-562.
27. Licata, M., et al., *Maternal Emotional Availability and Its Association with Maternal Psychopathology, Attachment Style Insecurity and Theory of Mind*. *Psychopathology*, 2016.
28. Mason, Z.S., R.D. Briggs, and E.J. Silver, *Maternal attachment feelings mediate between maternal reports of depression, infant social-emotional development, and parenting stress*. *Journal of Reproductive and Infant Psychology*, 2011. **29**(4): p. 382-394.
29. Hay, D.F., et al., *Intellectual problems shown by 11-year-old children whose mothers had postnatal depression*. *Journal of Child Psychology and Psychiatry*, 2001. **42**(7): p. 871-889.
30. Meaney, M.J., *Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations*. *Annual review of neuroscience*, 2001. **24**(1): p. 1161-1192.
31. Müller, M., et al., *Effects of Maternal Anxiety Disorders on Infant Self-Comforting Behaviors: The Role of Maternal Bonding, Infant Gender and Age*. *Psychopathology*, 2016. **49**(4): p. 295-304.
32. Dalsant, A., et al., *Maternal bonding in childhood moderates autonomic responses to distress stimuli in adult males*. *Behavioural Brain Research*, 2015. **292**: p. 428-431.
33. Hellhammer, D. and J. Hellhammer, *Stress: the brain-body connection*. 2008: Karger Medical and Scientific Publishers.
34. Brennan, P.A., et al., *Maternal depression and infant cortisol: influences of timing, comorbidity and treatment*. *Journal of Child Psychology and Psychiatry*, 2008. **49**(10): p. 1099-1107.
35. Fernandes, M., et al., *Foetal exposure to maternal depression predicts cortisol responses in infants: findings from rural South India*. *Child: care, health and development*, 2015. **41**(5): p. 677-686.
36. Kaplan, L.A., L. Evans, and C. Monk, *Effects of mothers' prenatal psychiatric status and postnatal caregiving on infant biobehavioral regulation: can prenatal programming be modified?* *Early human development*, 2008. **84**(4): p. 249-256.
37. Champagne, F.A., *Epigenetic mechanisms and the transgenerational effects of maternal care*. *Frontiers in neuroendocrinology*, 2008. **29**(3): p. 386-397.
38. Benoit, D. and K.C. Parker, *Stability and transmission of attachment across three generations*. *Child development*, 1994. **65**(5): p. 1444-1456.
39. Main, M. and E. Hesse, *Parents' unresolved traumatic experiences are related to infant disorganized attachment status: Is frightened and/or frightening parental behavior the linking mechanism?* 1990.
40. Pederson, D.R., et al., *Maternal attachment representations, maternal sensitivity, and the infant-mother attachment relationship*. *Developmental psychology*, 1998. **34**(5): p. 925.
41. Miller, L., et al., *Intergenerational transmission of parental bonding among women*. *Journal of the American Academy of Child & Adolescent Psychiatry*, 1997. **36**(8): p. 1134-1135.
42. Bakermans-Kranenburg, M.J., M.H. van Ijzendoorn, and F. Juffer, *Less is more: Meta-analyses of sensitivity and attachment interventions in early childhood*. *Psychological Bulletin*, 2003. **129**(2): p. 195-215.
43. Kalinauskiene, L., et al., *Supporting insensitive mothers: The Vilnius randomized control trial of video-feedback intervention to promote maternal sensitivity and infant attachment security*. *Child: Care, Health and Development*, 2009. **35**(5): p. 613-623.
44. Bilszta, J.L.C., et al., *Use of video feedback intervention in an inpatient perinatal psychiatric setting to improve maternal parenting*. *Archives of Women's Mental Health*, 2012. **15**(4): p. 249-257.
45. Teti, D.M., et al., *Intervention with African American premature infants: Four-month results of an early intervention program*. *Journal of Early Intervention*, 2009. **31**(2): p. 146-166.
46. Hoffenkamp, H.N., et al., *Effectiveness of hospital-based video interaction guidance on parental interactive behavior, bonding, and stress after preterm birth: A randomized controlled trial*. *Journal of Consulting and Clinical Psychology*, 2015. **83**(2): p. 416-429.
47. Daniel, R. and S. Pollmann, *A universal role of the ventral striatum in reward-based learning: evidence from human studies*. *Neurobiology of learning and memory*, 2014. **114**: p. 90-100.
48. Flagel, S.B., et al., *Individual differences in the propensity to approach signals vs goals promote different adaptations in the dopamine system of rats*. *Psychopharmacology*, 2007. **191**(3): p. 599-607.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
49. Adolphs, R., *The Social Brain: Neural Basis of Social Knowledge*. Annual Review of Psychology, 2009. **60**(1): p. 693-716.
50. Bhanji, J.P. and M.R. Delgado, *The social brain and reward: social information processing in the human striatum*. Wiley Interdisciplinary Reviews: Cognitive Science, 2014. **5**(1): p. 61-73.
51. Montoya, J.L., et al., *Regional brain responses in nulliparous women to emotional infant stimuli*. PLoS One, 2012. **7**(5): p. e36270.
52. Lenzi, D., et al., *Neural basis of maternal communication and emotional expression processing during infant preverbal stage*. Cerebral cortex, 2008. **19**(5): p. 1124-1133.
53. DelDonno, S.R., et al., *Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder*. Psychiatry research, 2015. **230**(1): p. 56-64.
54. Zhang, W.-N., et al., *The neural correlates of reward-related processing in major depressive disorder: a meta-analysis of functional magnetic resonance imaging studies*. Journal of affective disorders, 2013. **151**(2): p. 531-539.
55. Laurent, H.K. and J.C. Ablow, *A cry in the dark: depressed mothers show reduced neural activation to their own infant's cry*. Social Cognitive and Affective Neuroscience, 2012. **7**(2): p. 125-134.
56. Wonch, K.E., et al., *Postpartum depression and brain response to infants: Differential amygdala response and connectivity*. Social neuroscience, 2016: p. 1-18.
57. Dölen, G., et al., *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin*. Nature, 2013. **501**(7466): p. 179.
58. Ebner, N.C., et al., *Associations between oxytocin receptor gene (OXTR) methylation, plasma oxytocin, and attachment across adulthood*. 2018.
59. King, L., et al., *Perinatal depression and DNA methylation of oxytocin-related genes: a study of mothers and their children*. 2017. **96**: p. 84-94.
60. Galbally, M., et al., *Maternal depression, antidepressant use and placental oxytocin receptor DNA methylation: Findings from the MPEWS study*. 2018. **90**: p. 1-8.
61. Feldman, R., *Oxytocin and social affiliation in humans*. Hormones and Behavior, 2012. **61**(3): p. 380-391.
62. Thibault, R.T., et al., *Neurofeedback with fMRI: A critical systematic review*. NeuroImage, 2017.
63. Sulzer, J., et al., *Real-time fMRI neurofeedback: progress and challenges*. Neuroimage, 2013. **76**: p. 386-399.
64. Buyukturkuglu, K., et al., *Self-regulation of anterior insula with real-time fMRI and its behavioral effects in obsessive-compulsive disorder: a feasibility study*. PloS one, 2015. **10**(8): p. e0135872.
65. Paret, C., et al., *Alterations of amygdala-prefrontal connectivity with real-time fMRI neurofeedback in BPD patients*. Social cognitive and affective neuroscience, 2016. **11**(6): p. 952-960.
66. Zilverstand, A., et al., *fMRI neurofeedback facilitates anxiety regulation in females with spider phobia*. Frontiers in behavioral neuroscience, 2015. **9**.
67. Misaki, M., et al., *Real-time fMRI amygdala neurofeedback positive emotional training normalized resting-state functional connectivity in combat veterans with and without PTSD: a connectome-wide investigation*. 2018. **20**: p. 543-555.
68. Ditzen, B. and M. Heinrichs, *Psychobiology of social support: the social dimension of stress buffering*. Restor Neurol Neurosci, 2014. **32**(1): p. 149-62.
69. Cordes, J.S., et al., *Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia*. Frontiers in behavioral neuroscience, 2015. **9**.
70. Young, K.D., et al., *Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder*. PloS one, 2014. **9**(2): p. e88785.
71. Etkin, A., T. Egner, and R. Kalisch, *Emotional processing in anterior cingulate and medial prefrontal cortex*. Trends in Cognitive Sciences, 2011. **15**(2): p. 85-93.
72. Faul, F., et al., *Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses*. Behavior research methods, 2009. **41**(4): p. 1149-1160.
73. Tronick, E.Z., et al., *The infant's response to entrapment between contradictory messages in face-to-face interaction*. Journal of the American Academy of Child Psychiatry, 1978. **17**(1): p. 1-13.
74. Tronick, E.Z. and J.F. Cohn, *Infant-mother face-to-face interaction: age and gender differences in coordination and the occurrence of miscoordination*. Child Development, 1989. **60**(1): p. 85-92.

Eckstein et al NEMO study protocol

75. Feldman, R., *Coding interactive behavior manual*. Bar-Ilan University, Israel, 1998.
76. Reuner, G., & Rosenkranz, J., *Bayley-III - Bayley Scales of Infant & Toddler Development III. Deutsche Version*. 2015, Frankfurt: Pearson Assessment & Information GmbH.
77. Tronick, E.Z., T.B. Brazelton, and H. Als, *The structure of face-to-face interaction and its developmental functions*. Sign Language Studies, 1978. **18**: p. 1-16.
78. Schneider, S., et al., *Diagnostisches Interview bei psychischen Störungen (DIPS)*. 2006: Berlin: Springer.
79. Bifulco, A., et al., *Adult attachment style. I: Its relationship to clinical depression*. 2002. **37**(2): p. 50-59.
80. Bergant, A., et al., *Deutschsprachige Fassung und Validierung der» Edinburgh postnatal depression scale «*. DMW-Deutsche Medizinische Wochenschrift, 1998. **123**(03): p. 35-40.
81. Ehlers, A., J. Margraf, and D. Chambless, *Fragebogen zu körperbezogenen Ängsten, Kognitionen und Vermeidung (AKV)*. 2001, Göttingen: Beltz Test.
82. Lips, H.M. and K. Bloom, *Psychometric Evaluation of a New Scale to Measure Maternal Self-Confidence*. 1993: Radford.
83. Parker, G., H. Tupling, and L.B. Brown, *A Parental Bonding Instrument*. British Journal of Medical Psychology, 1979. **52**(1): p. 1-10.
84. Schumacher, J., M. Eisemann, and E. Brähler, *Fragebogen zum erinnerten elterlichen Erziehungsverhalten*. 2000: Huber.
85. Ehrenthal, J., et al., *Evaluation der deutschsprachigen Version des bindungsfragebogens 'Experiences in Close Relationships-Revised' (ECR-RD)*. Psychotherapie Psychosomatik Medizinische Psychologie, 2009. **59**(6): p. 215-223.
86. Fydrich, T., G. Sommer, and E. Brähler, *Fragebogen zur Sozialen Unterstützung (F-SozU). Manual*. Göttingen: Hogrefe.
87. Zimmermann, J., et al., *The structure and correlates of self-reported DSM-5 maladaptive personality traits: Findings from two German-speaking samples*. Journal of Personality Disorders, 2014. **28**(4).
88. Klinitzke, G., et al., *[The German Version of the Childhood Trauma Questionnaire (CTQ): psychometric characteristics in a representative sample of the general population]*. Psychother Psychosom Med Psychol, 2012. **62**(2): p. 47-51.
89. Hahlweg, K., *Fragebogen zur Partnerschaftsdiagnostik*. 1996, Göttingen: Hogrefe.
90. Bodenmann, G., *Dyadisches coping inventar: Testmanual [Dyadic coping inventory: Test manual]*. Bern, Switzerland: Huber, 2008.
91. Tröster, H., *Eltern-Belastungs-Inventar (EBI). Deutsche Version des Parenting Stress Index (PSI) von R. R. Abidin*. 2010: Manual Göttingen: Hogrefe.
92. Bifulco, A., et al., *The Vulnerable Attachment Style Questionnaire (VASQ): an interview-based measure of attachment styles that predict depressive disorder*. Psychological Medicine, 2003. **33**(6): p. 1099-1110.
93. Pauli-Pott, U., B. Mertesacker, and D. Beckmann, *Ein Fragebogen zur Erfassung des «frühkindlichen Temperaments» im Elternurteil*. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 2003. **31**(2): p. 99-110.
94. Martin-Soelch, C., et al., *Reduced response to reward in smokers and cannabis users*. Neuropsychobiology, 2009. **60**(2): p. 94-103.
95. Wessa, M., et al., *Fronto-striatal overactivation in euthymic bipolar patients during an emotional go/nogo task*. American Journal of Psychiatry, 2007. **164**(4): p. 638-646.
96. Scheele, D., et al., *Oxytocin enhances brain reward system responses in men viewing the face of their female partner*. Proceedings of the National Academy of Sciences, 2013. **110**(50): p. 20308-20313.
97. Schwartz, E.P., et al., *Assessing salivary cortisol in studies of child development*. Child Development, 1998. **69**(6): p. 1503-1513.
98. Feldman, R., *Coding interactive behavior manual*. 1998, Bar-Ilan University, Israel.
99. Feldman, R., S. Masalha, and R. Nadam, *Cultural perspective on work and family: dual-earner Israeli-Jewish and Arab families at the transition to parenthood*. J Fam Psychol, 2001. **15**(3): p. 492-509.
100. Pruessner, J.C., et al., *Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change*. Psychoneuroendocrinology, 2003. **28**(7): p. 916-931.
101. Stalder, T., et al., *Assessment of the cortisol awakening response: Summary of the ISPNE expert consensus guidelines*. Psychoneuroendocrinology, 2016. **71**: p. 44.

Eckstein et al NEMO study protocol

- 1
2
3 102. Feldman, R. and S. Masalha, *Parent-child and triadic antecedents of children's social*
4 *competence: Cultural specificity, shared process*. Developmental Psychology, 2010. **46**(2): p.
5 455.
- 6 103. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Administration*
7 *Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
- 8 104. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Technical*
9 *Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
- 10 105. Albers, C.A. and A.J. Grieve, *Test review: Bayley, N.(2006). Bayley scales of infant and*
11 *toddler development-third edition. San Antonio, TX: Harcourt assessment*. Journal of
12 *Psychoeducational Assessment*, 2007. **25**(2): p. 180-190.
- 13 106. Reck, C., et al., *Maternal avoidance, anxiety cognitions and interactive behaviour predicts*
14 *infant development at 12 months in the context of anxiety disorders in the postpartum period*.
15 *Infant Behavior and Development*, 2018. **50**: p. 116-131.
- 16 107. Gerchen, M.F., et al., *The SyBil-AA real-time fMRI neurofeedback study: protocol of a single-*
17 *blind randomized controlled trial in alcohol use disorder*. BMC Psychiatry, 2018. **18**(1): p. 12.
- 18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eckstein et al NEMO study protocol

AUTHORS' CONTRIBUTION STATEMENT:

B.D., P.K., A.L.Z. and M.E. designed the study; M.E. and A.L.Z. lead the study; S.A.J. collected data; P.K., M.F.G. and M.M.S. established the experimental set-up; S.A.J., A.L.Z and ME wrote the manuscript; All authors provided comments on the manuscript.

ACKNOWLEDGEMENTS:


The authors wish to thank Britta Zipser, Ekaterina Schneider, Madgalena Vragovic, Elena Augenstein, Johanna Jübner, Antonia Hüge, Corinna Abdaoui, Nora Nonnenmacher, Nina Schlegel, Josephine Parol and Hanna-Sophie Lässig for their assistance with conducting the study.

FUNDING STATEMENT:



This work was supported by the Dietmar-Hopp Foundation (September 2017- March 2020). The funding agency had no role in the planning of the study design and will not be involved in data collection, analysis, decision to publish or preparation of the manuscript.




COMPETING INTERESTS STATEMENT:

The authors declare that they have no competing interests.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



-  = Maternal Bloodsample
-  = HRV Mother and Infant
-  = Infant Cortisol Level

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	23
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	23
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	23

1	sponsor contact		
2	information		
3			
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;
5	responsibilities:		collection, management, analysis, and interpretation of
6	sponsor and funder		data; writing of the report; and the decision to submit the
7			report for publication, including whether they will have
8			ultimate authority over any of these activities
9			
10			
11			
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating
13	responsibilities:		centre, steering committee, endpoint adjudication
14	committees		committee, data management team, and other individuals or
15			groups overseeing the trial, if applicable (see Item 21a for
16			data monitoring committee)
17			
18			
19			
20	Background and	#6a	Description of research question and justification for
21	rationale		undertaking the trial, including summary of relevant studies
22			(published and unpublished) examining benefits and harms
23			for each intervention
24			
25			
26			
27	Background and	#6b	Explanation for choice of comparators
28	rationale: choice of		
29	comparators		
30			
31			
32	Objectives	#7	Specific objectives or hypotheses
33			
34			
35	Trial design	#8	Description of trial design including type of trial (eg, parallel
36			group, crossover, factorial, single group), allocation ratio,
37			and framework (eg, superiority, equivalence, non-inferiority,
38			exploratory)
39			
40			
41			
42	Study setting	#9	Description of study settings (eg, community clinic,
43			academic hospital) and list of countries where data will be
44			collected. Reference to where list of study sites can be
45			obtained
46			
47			
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,
49			eligibility criteria for study centres and individuals who will
50			perform the interventions (eg, surgeons, psychotherapists)
51			
52			
53			
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow
55	description		replication, including how and when they will be
56			administered
57			
58			
59			
60			

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	
8	adherence		and any procedures for monitoring adherence (eg, drug	
9			tablet return; laboratory tests)	
10				
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-14
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	10
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	10
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	9
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	9
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	10
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	15
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	15
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	2
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	23
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

and disclosure of contractual agreements that limit such access for investigators

1			
2			
3			
4	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for
5	trial care		compensation to those who suffer harm from trial
6			participation
7			
8			
9	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial
10	trial results		results to participants, healthcare professionals, the public,
11			and other relevant groups (eg, via publication, reporting in
12			results databases, or other data sharing arrangements),
13			including any publication restrictions
14			
15			
16			
17	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of
18	authorship		professional writers
19			
20			
21	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,
22	reproducible		participant-level dataset, and statistical code
23	research		
24			
25			
26			
27	Informed consent	#32	Model consent form and other related documentation given
28	materials		to participants and authorised surrogates
29			
30			
31	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of
32			biological specimens for genetic or molecular analysis in the
33			current trial and for future use in ancillary studies, if
34			applicable
35			
36			

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027747.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Feb-2019
Complete List of Authors:	Eckstein, Monika; UniversitätsKlinikum Heidelberg, Zietlow, Anna-Lena; UniversitätsKlinikum Heidelberg, Institute for Medical Psychology Gerchen, Martin; Central Institute for Mental Health, Department of Clinical Psychology Schmitgen, Mike; UniversitätsKlinikum Heidelberg, Department of General Psychiatry Ashcroft-Jones, Sarah; UniversitätsKlinikum Heidelberg Kirsch, Peter; Central Institute for Mental Health, Department of Clinical Psychology; Bernstein Center for Computational Neuroscience Ditzen, Beate; UniversitätsKlinikum Heidelberg, Institute of Medical Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Radiology and imaging
Keywords:	mother-infant bonding, maternal bonding difficulties, ventral striatum, oxytocin, functional magnetic resonance imaging (fMRI) neurofeedback, dopamine

SCHOLARONE™
Manuscripts

Eckstein et al NEMO study protocol

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

*Monika Eckstein¹, *Anna-Lena Zietlow¹, Martin Fungisai Gerchen^{2,3}, Mike Michael Schmitgen⁴, Sarah Ashcroft-Jones¹, Peter Kirsch^{2,3}, *Beate Ditzen¹

¹Institute of Medical Psychology, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

²Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.

³Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.

⁴Department of General Psychiatry, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

* contributed equally to this paper

Key words: mother-infant bonding, maternal bonding difficulties, ventral striatum, functional magnetic resonance imaging (fMRI) neurofeedback, oxytocin, dopamine

Word Count (Excluding title page, abstract, references, figures and tables): 5915

*Corresponding Authors:

Monika Eckstein, Anna-Lena Zietlow and Beate Ditzen

Institute of Medical Psychology,

Centre for Psychosocial Medicine,

Heidelberg University Hospital, Heidelberg University,

Bergheimer Str. 20,

69115 Heidelberg,

Germany

Email: monika.eckstein@med.uni-heidelberg.de

anna-lena.zietlow@med.uni-heidelberg.de

beate.ditzen@med.uni-heidelberg.de

Tel: +49 (0) 2221 56-7871

Eckstein et al NEMO study protocol

ABSTRACT:

Introduction:

Most mothers feel an immediate, strong emotional bond with their new-born. On a neurobiological level, this is accompanied with the activation of the brain's reward system, specifically the striatal dopaminergic region. However, approximately 10% of all mothers report difficulties to bond emotionally with their infant and display impaired reward responses to the interaction with their infant which might have long-term negative effects for the child's development.

As previous studies suggest that activation of the striatal reward system can be regulated through Functional Magnetic Resonance Imaging (fMRI) based Neurofeedback (NFB), we conceptualized and offer fMRI-NFB training to treat maternal bonding difficulties.

Methods and analysis:

In the planned trial, mothers will be presented pictures of their infant and real-time fMRI, peripheral measures, neural, endocrine, psychophysiological and behavioural measures will be assessed. Mothers with bonding difficulties (N= 68) will be randomised to one of two double blind intervention groups at 4-6 months postpartum. They will participate in three repeated neurofeedback training sessions with rtfMRI NFB training to increase activation of a) the ventral striatum or b) the anterior cingulate. Interview data and real-time mother-infant interaction behaviour pre-, post-intervention and at follow-up will serve as clinical outcome measures.

Ethics and Dissemination:

Study procedures are in line with the recommendations of the World Medical Association (revised Declaration of Helsinki) and were approved by the Ethics Committee of the Medical Faculty, s-450/2017, Heidelberg University. All participants will provide written informed consent after receiving a detailed oral and written explanation of all procedures and can withdraw their consent at any time without negative consequence.

Results will be internationally published and disseminated, to further the discussion on non-pharmacological treatment options in complex mental disorders.

Trial registration details:

The study is registered in the German Register for Clinical Trials (DRKS) DRKS00014570.

Eckstein et al NEMO study protocol

ARTICLE SUMMARY:

Strengths and Limitations of this Study:

- The novelty of used methods allow the investigation of the effect of real-time Functional Magnetic Imaging (rtfMRI) neurofeedback (NFB), on maternal bonding.
- The study investigates the ability of rtfMRI NFB to upregulate brain activity in correlation with behavioural and biopsychological markers.
- The simultaneous investigation of two brain regions as well as the presence of a control group proposed in the methods of this protocol enables a comparative analysis of the benefits of the rtfMRI training, as well as increasing clarity regarding the role of differential brain regions in social reward.
- The proposed method, through its' longitudinal design with follow-up measures, will help to evidence how neurofeedback training brings about behavioural change, in turn allowing for better understanding of the potential applications, predictive neural signatures and participant criteria crucial for the success of rtfMRI.
- Due to the statistical co-occurrence of maternal bonding difficulties and postpartum depression and the similar pattern of muted reward responses in both instances, the explanatory power of the results of the rtfMRI NFB intervention may be confounded.

INTRODUCTION:

The Neurobiological, Emotional and Behavioural Aspects of Maternal Bonding:

The parental bond is the first social bond that infants experience in life. Usually, it is the mother who serves as the child's immediate and most central social interaction partner. Maternal bonding is reflective of the first emotional bond that a mother gradually develops with her infant, within the first weeks postpartum, and is characterized by positive feelings, emotional warmth and affection towards the infant,[1]. In the eyes of some researchers, maternal bonding represents one of the most important psychological processes that gradually unfold after birth,[2] and is a significant and central aspect of the emerging relationship between mother and infant,[3].

The initial period after birth is also known as the "Baby-Honeymoon", a state of euphoria and happiness fuelled by the desire to constantly be near and to "fall in love" with the infant, which allows the mother to take on the challenges of the adaption to parenthood. In this way, maternal bonding also fulfils a biological function by ensuring the care for and subsequent survival of the new-born,[4]. On the behavioural level maternal bonding emerges through touch, eye-contact, use of "motherese", and the smiling at or caressing of the infant,[5]. Maternal bonding can therefore said to be expressed in the caregiving behaviours of the parent, in their focus on and high level of sensitivity to the needs of the infant,[6]. On the other hand, maternal bonding is also formed in the mother's emotions and thoughts about the infant and in the mental representations of motherhood that the mother holds,[7].

The strength of maternal bonding can also be demonstrated on a neurobiological level,[8]. Central structures such as the striatum, ventral tegmental area, amygdala, septum and hypothalamus are involved in affiliative behaviour, together with a combination of neurotransmitters and modulators such as dopamine and oxytocin[9, 10]. For affiliative traits, it has been proposed that those are mediated by dopaminergic projections from the ventral tegmental area and endogenous opioids in the hypothalamus with projections to the septum, especially during physical contact [11], that underlie rewarding feelings of affiliation.

One finding of central relevance to maternal bonding in particular is that mothers who report a good emotional bonding to their infant show increased reward-related activation in dopaminergic brain regions (the nucleus accumbens in the ventral striatum) in response to infant stimuli,[12]. These effects are particularly evident in the mother, in comparison to other caregivers, and have been assumed to be reinforced through the hormonal changes that accompany both birth and breast-feeding behaviours,[13, 14].

However, the bonding process is not always successful,[15, 16] and impaired maternal bonding can lead to avoidance or ambivalent emotions or behaviour in the mother. Impaired bonding can result not only in a lack of affection but also, in extreme cases, in the immediate rejection or neglect of the infant, as well as the possible presence of hostility or aggressive impulses,[2, 7]. Although postpartum bonding difficulties also occur in psychologically healthy mothers, they are observed particularly in the context of postpartum depression,[17, 18]. In a representative German sample 6.4% of psychologically healthy mothers reported difficulties in establishing emotional bonding with their infant. In depressed mothers the rate of prevalence is significantly higher at 17-29%,[19]. Furthermore, it has been shown that even subclinical depressive symptoms may negatively affect the developing bonding during the first months postpartum,[20].

Depression during the postpartum period itself is generally characterised by loss of interest or joylessness, insomnia, feelings of guilt, difficulties concentrating and, in severe cases, suicidal tendencies. Intense feelings and self-blame about being a bad mother are also often reported,[21]. On a neurobiological level, postpartum depression relates to a reduced level of reactivity in the striatal reward system, for example in the putamen,[22], but also the amygdala network [23] together with endocrine changes in the serotonin and steroid systems [24]. Studies show that in particular the mother-infant relationship,[25, 26], as well

Eckstein et al NEMO study protocol

as the actual mother-infant interaction,[27], both short and long-term can be impaired by peri- and postpartum depression,[25, 28]. Results of a recent study suggest that the link between maternal depressive symptoms at 2 months postpartum and maternal report about interaction with the infant at 6 months was mediated by maternal feelings of attachment,[29]. The present study focuses on bonding impairments, rather than postpartum depression, although there will be inevitable co-occurrence in the participant sample.

Research indicates that experiences and interaction in the “sensitive” postpartum period have long term consequences for the cognitive as well as socio-emotional development in children,[25, 30]. Animal studies have also demonstrated that positive caring behaviours of the mother positively influence offspring brain development and long-term stress-coping behaviours even in the next generation via epigenetic changes,[31]. Conversely, in humans, decreased maternal bonding can result in higher rates of self-directed affect regulation strategies and increased stress-reactivity [32] of the infant, as well as variable self-comfort behaviours, moderated by the infant’s gender and age,[32]. Research also indicates that restrained (distant) maternal behaviour can have far-reaching negative consequences for self-regulation, social behaviour and stress management in the infant [25, 30], even into adulthood with potential influences on own parenting behaviour,[33]. Furthermore, the association between maternal depression, anxiety disorders and stress-reactivity with changes in the hypothalamic-pituitary-adrenocortical axis (HPA axis) is well-documented,[34]. Indeed, recent studies indicate that infant exposure to maternal mental disorders can increase infant baseline cortisol levels, as the main outcome of the HPA axis, in the case of maternal depression and increase infant cortisol reactivity in cases of maternal anxiety,[35]. In a lower income setting, exposure to variable intensities of maternal depression demonstrated a U-shaped response curve in infant cortisol reactivity levels in the context of immunisation. Those with exposure to moderate-maternal depression levels demonstrated the lowest cortisol reactivity during immunisation,[36]. The importance of the influence of maternal interaction behaviours themselves is also clear. One particular study demonstrates, for example, that maternal sensitivity during the interaction with their infant has a moderating influence between maternal mental health during pregnancy and infant salivary cortisol levels,[37]. Given data on the transgenerational transmission of maternal care via epigenetics,[38], both in maternal-infant bonding,[39-41] and care-giving behaviours,[42] the importance of effective treatment and intervention plans are evident.

Current inpatient and outpatient mother-infant therapies, established in the context of postpartum mental disorders, focus not only on the disorder-specific treatment but also on specific elements for the promotion of the mother-infant relationship (e.g. baby massage and video feedback methods). Video feedback interventions have been shown to have a positive influence on mother-infant interaction,[43, 44] as well as the maternal self-efficacy in interacting and coping with the infant,[45, 46]. To our knowledge, maternal bonding has thus far only been recorded as an outcome variable in one study using video feedback invention,[47]. This intervention demonstrated improvements in maternal bonding; however, the participant pool only included mentally healthy women without postpartum bonding problems. Thus, interventions focussing on maternal bonding in women experiencing difficulties forming an emotional bond to their infant are urgently needed. Presently, such interventions or findings, directly relating maternal bonding difficulties and their effects on the infant’s stress reactivity in either biological or behavioural domains, are still lacking and in particular non-pharmacological treatment concepts would substantially broaden the treatment options for affected mothers and their infants.

Reward Learning in Depression and its Relation to Postpartum Bonding Difficulties:

On a neural level the dopamine-mediated reward system (specifically the ventral striatum and the nucleus accumbens) is crucial to the rewarding aspects of social interaction,[48, 49]. The ventral striatum also appears to be specifically involved in learning rewarding stimuli,

Eckstein et al NEMO study protocol

where high neural activation, correlated with the "BOLD response" in the fMRI, is accompanied by an increased dopaminergic response,[48]. As part of the learning process this reward activation is first triggered by primary enhancers, such as glucose, and over the course of the learning process transfers to secondary enhancers, such as food or money. In humans, from early in life, repeated positive social experiences can be seen as very strong reward and provided the basis for the much discussed "social brain hypothesis", in brain research [50, 51].

Images of happy children are generally perceived as positive by healthy individuals and activate the striatal areas of the brain,[52]. Psychologically healthy mothers also show a differential neural activation response to visual stimuli of happy children, as compared with stimuli of more ambiguous facial expressions of children. Expressions of joy activated the right limbic and paralimbic areas, by comparison ambiguous expressions correlated to activity in the left higher cognitive and motor areas that are often linked to cognitive effort,[53]. Consequently, positively reinforcing activities that lead to such activation, i.e. positive social interaction, are likely to be subsequently performed more frequently. In the case of the presence of depressive symptoms, however, such neural activation (i.e. activation in striatal and limbic networks) seems to be diminished during positive social interactions, these activities are therefore perceived as less rewarding,[54, 55] and diminish the motivation for social contact. Mothers with depressive symptoms demonstrated reduced activation in subcortical and cortical limbic regions (amygdala, cingulate) and cortical regions involved in emotion regulation (including the frontal cortex, insula, anterior cingulate); in line with symptomology of diminished capacities to experience joy and to down-regulate anger, anxiety, or worry,[22, 23, 56]. Notably mothers with postpartum depression show a reduced activation in striatal reward areas in response to stimuli of their own children,[22, 23, 56].

On a neuroendocrine level, basic research suggests that in rodents social-interaction related reward is associated with receptor-activation for the neuropeptide oxytocin in the nucleus accumbens,[57]. Initial data in humans indicates, that methylation of the oxytocin receptor gene is associated with attachment in different phases of the individual's lifespan,[58] and higher methylation is associated with postpartum depression,[59]. Antidepressant treatment, in turn, is assumed to lower methylation,[60]. This may explain, on a neurobiological level, the correlation between postpartum depression and maternal bonding difficulties,[61]. However, no contemporary intervention has yet focussed on the perception of the mother-infant interaction in terms of reward and involved oxytocin-related outcomes as possible evaluation criteria.

rtfMRI NFB as a Treatment Method:

Neurofeedback (NFB) is a novel method which, through the visualization of real-time brain activation, allows an individual to consciously regulate one's own brain activation. While it is well-established that mental strategies modulate brain activation as measured by fMRI blood oxygen level dependent signal (BOLD), NFB asks participants to modulate activation in prescribed regions or even networks of their brain by their own volition and in response to the immediate feedback/ visualization of the related brain activation patterns,[62]. Thus, volunteers can learn to regulate the activation of a previously defined brain region (see,[63] for a review). NFB interventions have previously often used electroencephalography (EEG) and other electrophysiological methods to visualize and modulate activation in higher-cortical areas. However, smaller and deeper areas of the limbic and reward system can be imaged primarily with high-resolution magnetic resonance imaging (MRI). One previous study has proven that healthy volunteers can be trained to voluntarily increase their brain activation patterns that have been classified for affiliative emotions in the same individual subject using voxel pattern analyses [64]. From a therapeutic point of view, the targeted modulation of

Eckstein et al NEMO study protocol

specific brain areas and associated circuits via neurofeedback should be associated with the improvement of mental symptoms.

In initial clinical pilot studies, for example, patients with borderline personality disorder, anxiety or obsessive-compulsive disorders have shown the ability to down regulate activation in the insula or the hyperactive amygdala in response to stress-related stimuli,[65-67]. Similarly, high risk alcohol consumers learned to down regulate the reward related activation of alcohol related stimuli,[68]. In PTSD patients, the changes in brain connectivity after fMRI neurofeedback correlate with the reduction of symptoms,[69]. Based on the previously articulated and evidenced notion of the psychobiological mechanisms underlying attachment and bonding as goal-oriented and reward-drive,[70], the proposed study looks to investigate whether specific activation of the ventral striatum can be voluntarily increased through training in the context of mother-infant bonding. Indeed in previous research, patients with major depressive disorders or schizophrenia were successfully trained to increase the activation of the hypoactive amygdala and the anterior cingulum in conjunction with positive stimuli,[71, 72]. Therefore, in line with the current understanding and treatment of mental illnesses, rtfMRI NFB represents a promising new intervention method for complex mental processes. Particularly important for understanding the potential of rtfMRI interventions is the transfer of the modulation of the BOLD signal towards behavioural changes,[62] which allows the value of this intervention form in a clinical setting to be distilled.

The Planned Trial:

In the planned double-blind randomized intervention trial (the “Neurofeedback for Mothers with Postpartum Bonding Difficulties Study”, “NeMo-Study”), three central points will be addressed.

1. Women with postpartum bonding difficulties (including women with postpartum depression) will be compared to healthy unaffected women in terms of reward-related brain activation to pictures showing their own infant and control stimuli. It is hypothesized that women with bonding difficulties show less brain response in the reward-related areas (ventral striatum) compared to the control group.
2. The clinical group will then undergo a regiment of NFB training. Participants will learn to consciously increase the activation of reward-associated brain areas (specifically the ventral striatum), or a control region (anterior cingulate cortex, ACC), during the presentation of images of their own infant. For ethical reasons, an active control treatment was chosen rather than joke or non-feedback. The activation of the central nervous dopamine system via the striatum is hypothesized to improve bonding motivation and social interaction behaviour. The coupling of infant stimuli to the central nervous reward activation should make it easier for these women to feel more joy in the real interaction,[62] with their infant post-training and to be more attentive and more sensitive in their interactions. Training of the dorsal/rostral ACC with a rather unspecific role in emotion regulation, such as e.g. in cognitive reappraisal,[73] or response inhibition [74], may have general beneficial effects as shown in another NFB study [71] but also indirectly influence parental affect regulation,. However, the more specific striatal feedback based on the rewarding aspects of the mother-child interaction are assumed to have stronger effects.
3. Effects of the NFB training will be related to the changes in behaviourally coded mother-infant interaction, maternal bonding quality and diagnostics, and epigenetic oxytocin receptor alterations, as assessed from peripheral blood. It is hypothesized that following the ventral striatum intervention, interaction, maternal bonding, and epigenetic markers will approximate the values of the healthy control group.

Eckstein et al NEMO study protocol

Thus, the study will address reward-related processes in impaired maternal bonding, observable changes on a behavioural and neuroendocrine level post-training - important steps in illustrating the validity of rtfMRI NFB as an intervention method,[62]. The proposed study is therefore well placed to produce a wealth of valuable and informative data, both regarding the potential scope of rtfMRI as a non-pharmacological intervention to young mothers.

METHODS AND ANALYSIS:

Design Overview:

To investigate points 1) – 3) (above) a controlled longitudinal study with randomised allocation of the two intervention groups to one of two anatomically defined regionally targeted areas in the NFB training will be employed. The two intervention groups will consist of mothers with identified maternal-bonding difficulties, while the control group will consist of psychologically-healthy mothers without bonding difficulties. The intervention groups will receive three NFB training sessions at intervals of approximately 14 days. Changes in maternal behaviours during mother-infant-interaction, measured using standardised coding of behavioural observations, will be assessed as the primary outcome measure. Possible alterations in oxytocin receptor methylation and gene expression will serve as secondary outcome measures. See Figure 1 for overview of study design and timeline (Figure 1).

[Figure 1: Overview of Study Design around here]

Participant Eligibility and Recruitment:

Eligible Participants:

Intervention Group: Mothers who report postpartum bonding difficulties, may present with a wide range of depressive symptoms.

Control Group: Psychologically healthy mothers with intact bonding to child.

Exclusion Criteria for all Groups:

Mothers: acute suicidality, bipolar or schizophrenic disorders, diagnosed dementia or substance abuse or substance dependency. Necessary fMRI exclusion criteria also apply.

Infants: multiple birth infants, preterm birth, confirmed physical or developmental disorders, which make participation impossible or unwise.

Participant Recruitment:

Participants will be recruited both online and by flyers disseminated through midwives, gynaecologists, paediatricians, in pharmacies and in maternity hospitals as well as mothering forums or self-help groups (e.g. "Shadow and Light") and registration offices. They receive thorough information about the study procedures both orally and in written form. The volunteer recruitment structure of the study makes it possible that given the intense feelings of self-blame symptomatic of the often co-occurring postpartum depression,[18] those most severely affected may not volunteer for the study. This limitation will be addressed via carefully worded and emphatic recruitment materials and processes.

Eckstein et al NEMO study protocol

Patient and Public Involvement

Patients and the general public were not involved in the design or implementation of this study. However, the participants are asked to report on the cognitive strategies they adopted during their rtfMRI NFB sessions and their subjective success with those strategies. These findings may inform future formulations of patient based NFB interventions.

The results of this study will not be disseminated to the participants directly but will be openly accessible online.

Screening assessment and group allocation:

Screening Assessment:

For inclusion in the study all potential participants will be screened (T0) prior to inclusion.

Random Group Assignment Procedure:

True random assignment to the two clinical intervention groups or the control group cannot occur due to the quasi-experimental nature of the design: The mothers are assigned to being clinical or control based on the quality of their postpartum bonding to their infant. Inclusion as part of the clinical intervention group is based on the categorical assessment of impaired maternal bonding using an in-depth interview based on the proposed criteria by,[19] and asked during the clinical interview. This approach additionally allows for the dimensional assessment of maternal-bonding impairments. Bonding assessment is further elaborated by the use of additional questionnaires exploring bonding impairment, such as the Postpartum Bonding Questionnaire 16 (PBQ-16), which holds an internal consistency of Cronbach's $\alpha=0.085$,[5].

Within the intervention group participants will be completely randomly and automatically assigned to one of the following two conditions: NFB of the right ventral striatum (clinical intervention group I) or NFB of the right anterior cingulate cortex (ACC) (clinical intervention group II). This randomisation is based on the order of inclusion into the study and pre-assigned lists that are double-blind in nature using nonpublic lists made by a colleague not involved in assessments and analyses. During all three intervention sessions, participants will be trained to modulate activation of the same pre-defined brain region (right ventral striatum or right ACC) based on the functional tasks during T1. Blinding of the treatment group will be revealed after the analyses at group level.

Power Analysis and Size Estimation:

The program G-Power v.3.1.9.2,[75] was used, in order to calculate the required sample size. To test the hypotheses mentioned above, a total of approximately $N = 100$ cases is estimated.

To perform a simple group comparison of maternal sensitivity between two treatment groups with a middle to large effect size ($d = 0.78$),[44] with a power of 90% and an alpha-error threshold of $p = .05$, a minimum group size of $N = 30$ for each clinical intervention group is required (I, NFB of the ventral striatum, II, NFB of the ACC). Assuming a drop-out rate of approx. 10%, an experimental sample of $N = 100$ will be aimed for in the projected study. With a repeated measures analyses and the T3 (follow-up) measurement the power is improved, which makes it possible to observe even medium effects with this planned sample.

$N = 68$ mothers with postpartum bonding difficulties will be included in the intervention ($N = 34$ to NFB region I ventral striatum, $N = 34$ to NFB region II ACC). Mental disorders, and especially postpartum depressive symptomatology, are measured in a multi-dimensional fashion through a structured clinical interview and a validated peri-partum

Eckstein et al NEMO study protocol

period questionnaire. Variability in depressive symptoms, ranging from none to moderate symptom-load is sought, thus allowing for appropriate and adequate statistical analysis of this covariate factor. As a control group N = 32 psychologically healthy women with a good bond with their infant will be recruited.

Pre- Post and Follow-Up Assessments (T1, T2 and T3):

Before (T1) and after the training (T2), participants will perform an extensive battery of diagnostic assessments characterizing the clinical aspects of bonding, including the instructed mother-child-interaction in the Face-To-Face-Still-Face-Paradigm,[76, 77]. A baseline fMRI session will assess the sensitivity of both the reward system and the limbic system using established fMRI tasks and blood samples will be collected for analysing hormonal and (epi-)genetic markers. After the end of the last neurofeedback training a post-intervention measurement (T2) and with 12 month a follow up (T3) will be performed using the same methods as at T1. At T3, mothers and infants will be instructed to freely play,[78] and videotaped. Age-specific markers of the infant's development will be coded using a standardized developmental test,[79]. (Refer to Figure 1 for timeline clarification).

This combination of assessments allows for a comprehensive understanding of maternal bonding and behaviour on a neural, neuroendocrine, epigenetic and behavioural level.

The primary behavioural outcome measures includes the quality of maternal-infant interaction behavior (composite scores of maternal and dyadic behavior) while on the neuronal level, we assess the BOLD response to positive stimuli of the child as primary outcome measure. Physiological, endocrine and genetic markers serve as secondary outcomes.

See Table 1 for further details on the assessments and scheduling of measure collection.

Survey instruments and Coding Systems used in the Study:

Measure	Citation	M.	F.	I.	T0	T1	N	T2	T3
Mother and infant:									
Mother-Infant Interaction (FFSF)	[76, 77]	X		X		X		X	
Free-Play Situation	[78]	X		X					X
Interviews:									
Diagnostic Interview for Mental Disorders	[80]	X							
Interview for Postpartum Bonding Difficulties		X	X						
Attachment Style Interview	[81]	X	X						
Questionnaires:									
Postpartum Bonding Questionnaire 16-R	[5]	X	X			X		X	X
Edinburgh Postnatal Depression Scale	[82]	X	X			X		X	X
Agoraphobic Cognitions Questionnaire, Body Sensations Questionnaire, and Mobility Inventory	[83]	X	X			X		X	X
Maternal Self-Confidence Scale	[84]	X	X			X			X
Prenatal Emotional Stress Index	[17]	X	X						
Parental Bonding Instrument	[85]	X	X			X			

Eckstein et al NEMO study protocol

German version of the EMBU questionnaire regarding remembered parenting behaviours	[86]	X	X		X		
Experiences in Close Relationships- Revised	[87]	X	X		X		
Social Support Questionnaire	[88]	X	X		X	X	X
Personality Inventory- DSM 5 Short Form	[89]	X	X		X		
Childhood Trauma Questionnaire	[90]	X	X		X		
Partnership Questionnaire	[91]	X	X		X	X	X
Dyadic Coping Inventory	[92]				X	X	X
Parenting Stress Inventory	[93]	X	X			X	X
Vulnerable Attachment Style Questionnaire	[94]	X	X		X		
Edinburgh Handedness Questionnaire	[95]						X
Infant:							
Infant Behaviour Questionnaire	[96]	X	X		X		X
Development Assessment: Infant							
Bayley's Infant Development Scale III	[79]		X				X
Physiological Measures							
Infant Saliva Sample			X		X	X	X
Mother Blood Sample		X			X	X	X
Neurofeedback Training							
Reward Task	[97]	X			X	X	X
Emotional Go-No-Go	[74]	X			X	X	X
Passive Viewing Task	[98]	X			X	X	X

Table 1: Schedule of measures used the in study. M. Mother Response, F. Father response, I. Infant response, T0 screening assessment, T1 baseline assessment, N-neurofeedback sessions, T2 post assessment, T3 follow-up.

Detailed Description of Measures, Methods and Instruments used:

Initial Assessments:

Baseline Assessment:

For the baseline testing period (T1) the mothers will be invited to our video-laboratory together with their infants. A structured clinical interview according to DSM-5 as well as an interview regarding postpartum bonding difficulties will be carried out. Subsequently, parent-infant interaction will be assessed and videotaped during the Face-to-Face-Still-Face (FFSF) paradigm, a widely used paradigm for evaluating the quality of early parent-infant interaction,[76]. To determine infant stress-reactivity, cortisol and alpha-amylase will be extracted from infant saliva according to standard protocols,[99], which is collected before (C1), immediately after (C2), 20 minutes (C3) and 30 minutes after the FFSF (C4).

Instructed Mother-infant interaction:

Mother-infant-interaction pre- post-intervention (T1 and T3): The standardised mother-infant-interaction before and after the intervention follows the established FFSF paradigm,[76, 77]. It consists of three consecutive instructed two-minute episodes in which the mother, with the infant seated in the baby chair, interacts in accordance with a fixed pattern: First, an initial face-to-face interaction in which the mothers are instructed to play with their infant as usual (without the aid of toys and pacifiers). Next, the still-face episode in which the mothers have to turn their head aside while silently counting to ten and then turn back to the infant but not engage in any gestures, facial expressions, or vocalizations. Finally, the procedure ends with

Eckstein et al NEMO study protocol

the reunion episode in which the mother is required to resume face-to-face play with her infant.

Mother-infant-interaction Follow-Up (T4): As the Still-face paradigm can be conducted up to the age of 9 months, parent-infant interaction will be assessed at T4 during a 15-minute free-play situation and a subsequent limit setting task. All interaction episodes will be videotaped and coded according to the Coding Infant Behaviour Scales (CIB),[100]. The CIB scales assess parental sensitivity and responsiveness as well as intrusiveness and withdrawal via composite scores,[101]).

Psychobiological Measurements:

Epigenetic Information on the Oxytocin-System and Cortisol/Alpha Amylase in Saliva:

Maternal blood samples are taken to examine the endogenous oxytocin level, gonadal hormones and epigenetic parameters of the oxytocin gene and oxytocin receptor gene. For the endocrine investigation of the stress hormone cortisol painless saliva samples are taken from the infants directly before, immediately after 20 and 30 minutes after the mother-infant interaction using a saliva probe. An elevation of infant stress-reactivity is expected during the interaction, from these elevations the Peak and Recovery be ascertained. The area under the curve is therefore analysed as a reactivity index,[102] as is standard practice,[103].

MRI-tasks:

Reward Task:

The task, (adapted from,[97]), requires participants to perform a spatial working memory task with two levels of cognitive load, differentiated by the number of circles to be remembered. Subjects first see a cue informing them of the potential monetary reward value – high or low. After presentation of the fixation cross, an array of yellow circles (3 or 7 circles), is displayed followed the target, a green circle, that is then presented at any position on the screen. The participants must decide whether this circle is in the same position as one of the circles presented previously. In the rewarded condition, a feedback about the win (followed by the cumulated amount of earned money appears. Correct responses are reinforced by two different amounts of monetary reward that are counterbalanced with the levels of cognitive load. Incorrect responses on rewarded trials result in no monetary gain. While performing the task, participants rate their mood and stress levels a quarter of the trials.

Emotional Go/NoGo:

The participants are presented with positive and negative expressions of unknown babies, unknown adults as well as un-social control stimuli (geometric figures; a circle, a cross, a diamond and a triangle) over three presentation blocks.

The following factors are systematically manipulated: child vs adult and emotionality of facial expression (positive vs negative). In two blocks, the participants receive instructions to respond by pressing a button as fast as possible to all facial expression except the negative (one block babies, one block adults). In two other blocks they are instructed to respond as fast as possible to all except the positive (one block babies, one block adults). In the two non-social blocks the participants should react as fast as possible to all shapes but not to a circle or a diamond,[74].

Passive Viewing Task:

The participants view previously collected neutral-positive images of partners and their babies in positive and negative affect, with instructions to observe carefully. Unfamiliar men and babies will serve as control stimuli. Viewing images of partners and children leads to the activation of a broad socio-emotional neural network, that is involved with empathy and socio-emotional cognition,[22, 98].

Eckstein et al NEMO study protocol

Coding Systems Used in the Study:

Coding Interactive Behaviour:

For the evaluation of the mother-child interaction over all measurement points the Coding Interactive Behaviour System will be used (CIB:[78]). The CIB is a widely used, global rating system for analysing mother-infant-interaction. The system uses multiple codes for the infants, parents and dyadic codes that aggregate into meaningful theoretically-based constructs (e.g., sensitivity, intrusiveness, reciprocity, social engagement, withdrawal). The psychometric characteristics are all well described,[104]. The mother-infant interaction will be coded by blind and reliable coders who are independent of the current study, 10-20% of the videos will be double coded for inter-rater reliability.

Infant Development Diagnostics used in the Study:

Bayley Scales of Infant and Toddler Development-III:

The Bayley Scales of Infant and Toddler Development-III (Bayley-III;[105, 106]) assess the development of infants and toddlers between one and 42 months of age. The test battery covers the domains of cognition, language, motor, social-emotional and adaptive development using I-Q-scaled composite scores. Whereas the first three aspects are assessed by behavioural observation and the latter two utilize questionnaires, with duration ranging between 50 and 90 min,[107]. The Cognitive Scale assesses sensory-motor development, exploration and manipulation, object relatedness, concept formation and memory. The Language Scale is composed of the two subscales receptive and expressive communication. Testing pre-verbal behaviour, vocabulary development, understanding of morphological markers, social referencing and verbal comprehension and pre-verbal communication, vocabulary development and morpho-syntactic development respectively. In addition, the Bayley Scales include a Gross- and Fine-Motor Scale, a Social-Emotional Scale, and an Adaptive Behaviour Scale. This study focuses on the language and cognitive composite scores due to the rather small proposed sample size.

The Bayley-III indices and subscales demonstrate good internal consistency and good split-half-consistency according to the Spearman-Brown formula,[107]. Regarding construct validity, confirmatory factor analysis of the subtests of the Cognitive, Language, and Motor scales supported a three-factor model across all ages. The Bayley-III scales have been normed for German infants and children,[108]. This method is taken standard internationally, particularly in terms of reviewing developmental delays and planning targeted early interventions. The order of the subtests can be adapted to the needs of the child.

Neurofeedback Setup:

The mothers with bonding difficulties will be randomised to receive one of the two following interventions: I) NFB for activation of the ventral striatum or II) neurofeedback for activation of the anterior cingulate cortex (ACC).

The individual masks for extraction of the neurofeedback value are built after the 1st level analyses of the reward task and the emotional go/nogo task submitting the peak voxel coordinates in the right ventral striatum and ACC based on the contrasts [reward > baseline] and [faces nogo > faces go] to build a 12mm-sphere for the striatum ROI and ACC using the marsbar toolbox,[109].

Participants will partake in NFB training over three sessions at intervals of approximately 14 days (refer to Figure 1). At baseline, a high-resolution structural MRI scan and the activation pattern based on the infant-like stimuli will be recorded (using a Tim Trio 3T MRI scanner, Siemens, Erlangen, Germany).

Each intervention session will last approximately 60 minutes and will begin with a 10minute preparatory structural MRI scan. A 6minute resting state fMRI scan is then conducted to allow a resting baseline to be established and to prepare the neurofeedback

Eckstein et al NEMO study protocol

set-up. Afterwards, three rtfMRI NFB runs of 9:29 minutes are conducted. During neurofeedback training positive and neutral pictures of the participants' own child taken from the recorded mother-infant interaction session will be presented together with an on-screen "thermometer" which represents the current intensity of activation in the striatum or ACC and must be upregulated. In each run, six alternating phases of up-regulation (~41 seconds, including a ~10 second initial period without thermometer display) and of rest (observation of a fixation cross, ~41 seconds) will be performed. (See Figure 2 for details). The women are instructed to try and explore different self-chosen strategies (of up-regulation) and find the one that works best for them. Afterwards, they are asked to report which strategy they used and about their subjective success experience. In the first and third scanning session the third run is implemented as a "transfer" block without the visible "thermometer" display,[66, 68, 72].

Functional images are acquired with a Siemens Tim Trio using a T2*-weighted echoplanar sequence (TR = 1.64s, TE = 30ms, 30 slices, 3mm slice thickness, FoV = 192mm, flip angle 73°, voxel size 3x3x3 mm, 343 volumes per trainings run, distance factor of 33% and GRAPPA with iPat = 2) and a 32 channel head coil. Control for cardiovascular parameters is conducted using the built-in pulse clip. In-house Matlab software based on SPM12 functions is used to conduct rtfMRI NFB and Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA) is used to present pictures and the feedback signal. At the beginning of each NFB training session, the anatomical image is segmented and normalized to MNI standard space. The inverse deformations of the normalization are then applied to warp the masks of the target regions into subject space.

To correct for movement, each acquired volume is realigned to the first image of the run. Then, volumes with more than 0.5 mm scan-to-scan movements are identified and marked in dummy regressors. Afterwards, the average intensity values from the target region and a cerebrospinal fluid (CSF) mask are extracted and the signal of the target region is corrected for the estimated motion parameters, high-motion dummy regressors, and the CSF signal. For calculation of the feedback signal the ROI intensity value of the last 3 volumes is averaged and compared to the average intensity of the baseline condition. For further technical details regarding the neurofeedback setup please refer to Gerchen et al [110] which uses an identical neurofeedback procedure in the context of alcohol addiction.

[Figure 2: Two Trials of the Neurofeedback Intervention within a Run around here]

Eckstein et al NEMO study protocol

Data Analysis Plan:

Statistical analyses, namely the main comparison of the two groups (mothers with bonding difficulties vs. the control group) and the longitudinal analysis of positive relationships changes after the NFB intervention (interaction behaviour, attachment data, as well as psychophysiological, neuroendocrine and epigenetic markers (see Table 1) will be done using IBM SPSS Statics and R (r-project.org). The MRI data will be analysed with general linear models using statistical parametric mapping with SPM (<https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) implemented (Wellcome Department of Cognitive Neurology, London, UK) in MATLAB (MathWorks, Natick, MA) MATLAB.

For all MRI tasks, all events of the paradigms are modelled by means of general linear model. The relevant contrasts for the go/nogo task are [faces nogo > faces go],[child faces nogo > adult faces nogo] and [negative faces nogo > positive faces nogo]. The relevant contrasts for the reward task are [reward high > reward low], [reward high cognitive load > reward low cognitive load] and [anticipation of reward > baseline]. The relevant contrasts for the passive viewing task are [own infant > unfamiliar child], [positive infant > negative infant], [own partner > unfamiliar man] and [own infant > own partner].

To calculate pre-, post- and follow-up group differences between the intervention and control groups, repeated measures ANOVAs will be calculated, while multi-level models will be used to model changes over the time course.

Eckstein et al NEMO study protocol

Figure Legends:

Figure 1:

Overview of Study Design

Figure 2:

Two Trials of the Neurofeedback Intervention within a Run

For peer review only

Eckstein et al NEMO study protocol

ETHICS AND DISSEMINATION:

Ethics, consent to participate and Dissemination:

Study procedures are in line with the recommendations of the World Medical Association (revised Declaration of Helsinki) and were approved by the Ethics Committee of the Medical Faculty, s-450/2017, Heidelberg University. The study is registered as clinical trial in the German Register for Clinical Trials (DRKS) DRKS00014570. All participants will provide written informed consent after receiving a detailed oral and written explanation of all procedures and can withdraw their consent at any time without negative consequence.

Results will be internationally published and disseminated, to further the discussion on non-pharmacological treatment options in complex mental disorders.

Consent for Publication:

Not applicable.

Availability of Data and Material

For protection of personal rights and due to the sensitivity of the clinical information, raw data will not be available in the public domain. The medical confidentiality and the provisions of the EU-DSG (Data Protection Act) are therefore complied with; the collected medical findings and / or personal information are recorded in the examination centre or stored electronically.

Furthermore, important data for the study are stored in an anonymised format, evaluated and, if necessary, passed on to the necessary persons. Third parties gain no insight into the original data with the database remaining restricted for scientific use only. If results are published, it will not be possible to draw any conclusions to an individual as the confidentiality of personal data remains guaranteed at all time

REFERENCES:

1. Klaus, M., Kennell, J., & Klaus, P., *Bonding*. 1995, New York: Addison-Wesley.
2. Brockington, I., *Postpartum psychiatric disorders*. Lancet, 2004. **363**(9405): p. 303-10.
3. Klaus, M.H. and J.H. Kennell, *Parent-infant bonding*. 2. ed. ed. 1982, St. Louis, Mo [u.a.]: Mosby. XIX, 313 S.
4. Maestripieri, D., *Is There Mother–Infant Bonding in Primates?* Developmental Review, 2001. **21**(1): p. 93-120.
5. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: psychometric properties and association with postpartum depression*. Archives of women's mental health, 2006. **9**(5): p. 265-271.
6. Tietz, A., A.-L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. Archives of women's mental health, 2014. **17**(5): p. 433-442.
7. Hornstein, C., E. Hohm, and P. Trautmann-Villalba, *Die postpartale Bindungsstörung: Eine Risikokonstellation für den Infantizid?* Forensische Psychiatrie, Psychologie, Kriminologie, 2009. **1**: p. 1-8.
8. Feldman, R., *The adaptive human parental brain: Implications for children's social development*. Trends in Neurosciences, 2015. **38**(6): p. 387-399.
9. Moll, J. and J. Schulkin, *Social attachment and aversion in human moral cognition*. Neuroscience & Biobehavioral Reviews, 2009. **33**(3): p. 456-465.
10. Moll, J., et al., *A neural signature of affiliative emotion in the human septohypothalamic area*. Journal of neuroscience, 2012. **32**(36): p. 12499-12505.
11. Depue, R.A. and J.V. Morrone-Strupinsky, *A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation*. Behav Brain Sci, 2005. **28**(3): p. 313-50; discussion 350-95.
12. Strathearn, L., et al., *What's in a smile? Maternal brain responses to infant facial cues*. Pediatrics, 2008. **122**(1): p. 40-51.
13. Bakermans-Kranenburg, M.J. and M.H.v. IJzendoorn, *Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting*. SCAN, 2008. **3**: p. 128-134.
14. Feldman, R., et al., *Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding*. Psychol Sci, 2007. **18**(11): p. 965-70.
15. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: Psychometric properties and association with postpartum depression*. Archives of Women's Mental Health, 2006. **9**(5): p. 265-271.
16. Brockington, I., H. Aucamp, and C. Fraser, *Severe disorders of the mother–infant relationship: definitions and frequency*. Archives of women's mental health, 2006. **9**(5): p. 243-251.
17. Moehler, E., et al., *Maternal depressive symptoms in the postnatal period are associated with long-term impairment of mother-child bonding*. Archives of Women's Mental Health, 2006. **9**(5): p. 273-278.
18. Reck, C., et al., *Perceived parenting stress in the course of postpartum depression: the buffering effect of maternal bonding*. Arch Womens Ment Health, 2016. **19**(3): p. 473-82.
19. Brockington, I.F., et al., *A screening questionnaire for mother-infant bonding disorders*. Archives of Women's Mental Health, 2001. **3**(4): p. 133-140.
20. Tietz, A., A.L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. Archives of Women's Mental Health, 2014. **17**(5): p. 433-42.
21. Hofecker-Fallahpour, M. and A. Riecher-Rössler, *Depression in der frühen Mutterschaft*. Neurotransmitter Sonderheft, 2003. **2**: p. 35-39.
22. Laurent, H.K. and J.C. Ablow, *A face a mother could love: depression-related maternal neural responses to infant emotion faces*. Social neuroscience, 2013. **8**(3): p. 228-239.
23. Wonch, K.E., et al., *Postpartum depression and brain response to infants: Differential amygdala response and connectivity*. Social neuroscience, 2016: p. 1-18.
24. Pawluski, J.L., J.S. Lonstein, and A.S. Fleming, *The Neurobiology of Postpartum Anxiety and Depression*. Trends in Neurosciences, 2017. **40**(2): p. 106-120.
25. Reck, C., N. Nonnenmacher, and A.L. Zietlow, *Intergenerational Transmission of Internalizing Behavior: The Role of Maternal Psychopathology, Child Responsiveness and Maternal Attachment Style Insecurity*. Psychopathology, 2016. **49**(4): p. 277-284.

Eckstein et al NEMO study protocol

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
26. Zietlow, A.-L., et al., *Maternal Self-confidence Postpartum and at Pre-school Age: The Role of Depression, Anxiety Disorders, Maternal Attachment Insecurity*. Maternal and Child Health Journal, 2014. **18**(8): p. 1873-1880.
27. Reck, C., et al., *Interactive coordination of currently depressed inpatient mothers and their infants during the postpartum period*. Infant Mental Health Journal, 2011. **32**(5): p. 542-562.
28. Licata, M., et al., *Maternal Emotional Availability and Its Association with Maternal Psychopathology, Attachment Style Insecurity and Theory of Mind*. Psychopathology, 2016.
29. Mason, Z.S., R.D. Briggs, and E.J. Silver, *Maternal attachment feelings mediate between maternal reports of depression, infant social-emotional development, and parenting stress*. Journal of Reproductive and Infant Psychology, 2011. **29**(4): p. 382-394.
30. Hay, D.F., et al., *Intellectual problems shown by 11-year-old children whose mothers had postnatal depression*. Journal of Child Psychology and Psychiatry, 2001. **42**(7): p. 871-889.
31. Meaney, M.J., *Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations*. Annual review of neuroscience, 2001. **24**(1): p. 1161-1192.
32. Müller, M., et al., *Effects of Maternal Anxiety Disorders on Infant Self-Comforting Behaviors: The Role of Maternal Bonding, Infant Gender and Age*. Psychopathology, 2016. **49**(4): p. 295-304.
33. Dalsant, A., et al., *Maternal bonding in childhood moderates autonomic responses to distress stimuli in adult males*. Behavioural Brain Research, 2015. **292**: p. 428-431.
34. Hellhammer, D. and J. Hellhammer, *Stress: the brain-body connection*. 2008: Karger Medical and Scientific Publishers.
35. Brennan, P.A., et al., *Maternal depression and infant cortisol: influences of timing, comorbidity and treatment*. Journal of Child Psychology and Psychiatry, 2008. **49**(10): p. 1099-1107.
36. Fernandes, M., et al., *Foetal exposure to maternal depression predicts cortisol responses in infants: findings from rural South India*. Child: care, health and development, 2015. **41**(5): p. 677-686.
37. Kaplan, L.A., L. Evans, and C. Monk, *Effects of mothers' prenatal psychiatric status and postnatal caregiving on infant biobehavioral regulation: can prenatal programming be modified?* Early human development, 2008. **84**(4): p. 249-256.
38. Champagne, F.A., *Epigenetic mechanisms and the transgenerational effects of maternal care*. Frontiers in neuroendocrinology, 2008. **29**(3): p. 386-397.
39. Benoit, D. and K.C. Parker, *Stability and transmission of attachment across three generations*. Child development, 1994. **65**(5): p. 1444-1456.
40. Main, M. and E. Hesse, *Parents' unresolved traumatic experiences are related to infant disorganized attachment status: Is frightened and/or frightening parental behavior the linking mechanism?* 1990.
41. Pederson, D.R., et al., *Maternal attachment representations, maternal sensitivity, and the infant-mother attachment relationship*. Developmental psychology, 1998. **34**(5): p. 925.
42. Miller, L., et al., *Intergenerational transmission of parental bonding among women*. Journal of the American Academy of Child & Adolescent Psychiatry, 1997. **36**(8): p. 1134-1135.
43. Bakermans-Kranenburg, M.J., M.H. van Ijzendoorn, and F. Juffer, *Less is more: Meta-analyses of sensitivity and attachment interventions in early childhood*. Psychological Bulletin, 2003. **129**(2): p. 195-215.
44. Kalinauskiene, L., et al., *Supporting insensitive mothers: The Vilnius randomized control trial of video-feedback intervention to promote maternal sensitivity and infant attachment security*. Child: Care, Health and Development, 2009. **35**(5): p. 613-623.
45. Bilszta, J.L.C., et al., *Use of video feedback intervention in an inpatient perinatal psychiatric setting to improve maternal parenting*. Archives of Women's Mental Health, 2012. **15**(4): p. 249-257.
46. Teti, D.M., et al., *Intervention with African American premature infants: Four-month results of an early intervention program*. Journal of Early Intervention, 2009. **31**(2): p. 146-166.
47. Hoffenkamp, H.N., et al., *Effectiveness of hospital-based video interaction guidance on parental interactive behavior, bonding, and stress after preterm birth: A randomized controlled trial*. Journal of Consulting and Clinical Psychology, 2015. **83**(2): p. 416-429.
48. Daniel, R. and S. Pollmann, *A universal role of the ventral striatum in reward-based learning: evidence from human studies*. Neurobiology of learning and memory, 2014. **114**: p. 90-100.
49. Flagel, S.B., et al., *Individual differences in the propensity to approach signals vs goals promote different adaptations in the dopamine system of rats*. Psychopharmacology, 2007. **191**(3): p. 599-607.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
50. Adolphs, R., *The Social Brain: Neural Basis of Social Knowledge*. Annual Review of Psychology, 2009. **60**(1): p. 693-716.
51. Bhanji, J.P. and M.R. Delgado, *The social brain and reward: social information processing in the human striatum*. Wiley Interdisciplinary Reviews: Cognitive Science, 2014. **5**(1): p. 61-73.
52. Montoya, J.L., et al., *Regional brain responses in nulliparous women to emotional infant stimuli*. PLoS One, 2012. **7**(5): p. e36270.
53. Lenzi, D., et al., *Neural basis of maternal communication and emotional expression processing during infant preverbal stage*. Cerebral cortex, 2008. **19**(5): p. 1124-1133.
54. DelDonno, S.R., et al., *Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder*. Psychiatry research, 2015. **230**(1): p. 56-64.
55. Zhang, W.-N., et al., *The neural correlates of reward-related processing in major depressive disorder: a meta-analysis of functional magnetic resonance imaging studies*. Journal of affective disorders, 2013. **151**(2): p. 531-539.
56. Laurent, H.K. and J.C. Ablow, *A cry in the dark: depressed mothers show reduced neural activation to their own infant's cry*. Social Cognitive and Affective Neuroscience, 2012. **7**(2): p. 125-134.
57. Dölen, G., et al., *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin*. Nature, 2013. **501**(7466): p. 179.
58. Ebner, N.C., et al., *Associations between oxytocin receptor gene (OXTR) methylation, plasma oxytocin, and attachment across adulthood*. 2018.
59. King, L., et al., *Perinatal depression and DNA methylation of oxytocin-related genes: a study of mothers and their children*. 2017. **96**: p. 84-94.
60. Galbally, M., et al., *Maternal depression, antidepressant use and placental oxytocin receptor DNA methylation: Findings from the MPEWS study*. 2018. **90**: p. 1-8.
61. Feldman, R., *Oxytocin and social affiliation in humans*. Hormones and Behavior, 2012. **61**(3): p. 380-391.
62. Thibault, R.T., et al., *Neurofeedback with fMRI: A critical systematic review*. NeuroImage, 2017.
63. Sulzer, J., et al., *Real-time fMRI neurofeedback: progress and challenges*. Neuroimage, 2013. **76**: p. 386-399.
64. Moll, J., et al., *Voluntary enhancement of neural signatures of affiliative emotion using FMRI neurofeedback*. PloS one, 2014. **9**(5): p. e97343.
65. Buyukturkuglu, K., et al., *Self-regulation of anterior insula with real-time fMRI and its behavioral effects in obsessive-compulsive disorder: a feasibility study*. PloS one, 2015. **10**(8): p. e0135872.
66. Paret, C., et al., *Alterations of amygdala-prefrontal connectivity with real-time fMRI neurofeedback in BPD patients*. Social cognitive and affective neuroscience, 2016. **11**(6): p. 952-960.
67. Zilverstand, A., et al., *fMRI neurofeedback facilitates anxiety regulation in females with spider phobia*. Frontiers in behavioral neuroscience, 2015. **9**.
68. Kirsch, M., et al., *Real-time functional magnetic resonance imaging neurofeedback can reduce striatal cue-reactivity to alcohol stimuli*. Addiction biology, 2015.
69. Misaki, M., et al., *Real-time fMRI amygdala neurofeedback positive emotional training normalized resting-state functional connectivity in combat veterans with and without PTSD: a connectome-wide investigation*. 2018. **20**: p. 543-555.
70. Ditzen, B. and M. Heinrichs, *Psychobiology of social support: the social dimension of stress buffering*. Restor Neurol Neurosci, 2014. **32**(1): p. 149-62.
71. Cordes, J.S., et al., *Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia*. Frontiers in behavioral neuroscience, 2015. **9**.
72. Young, K.D., et al., *Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder*. PloS one, 2014. **9**(2): p. e88785.
73. Etkin, A., T. Egner, and R. Kalisch, *Emotional processing in anterior cingulate and medial prefrontal cortex*. Trends in Cognitive Sciences, 2011. **15**(2): p. 85-93.
74. Wessa, M., et al., *Fronto-striatal overactivation in euthymic bipolar patients during an emotional go/nogo task*. American Journal of Psychiatry, 2007. **164**(4): p. 638-646.
75. Faul, F., et al., *Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses*. Behavior research methods, 2009. **41**(4): p. 1149-1160.

Eckstein et al NEMO study protocol

- 1
2
3 76. Tronick, E.Z., et al., *The infant's response to entrapment between contradictory messages in face-to-face interaction*. Journal of the American Academy of Child Psychiatry, 1978. **17**(1): p. 1-13.
- 4
5
6 77. Tronick, E.Z. and J.F. Cohn, *Infant-mother face-to-face interaction: age and gender differences in coordination and the occurrence of miscoordination*. Child Development, 1989. **60**(1): p. 85-92.
- 7
8
9 78. Feldman, R., *Coding interactive behavior manual*. Unpublished manual, Bar-Ilan University, Israel, 1998.
- 10
11 79. Reuner, G., & Rosenkranz, J. , *Bayley-III - Bayley Scales of Infant & Toddler Development III. Deutsche Version*. . 2015, Frankfurt: Pearson Assessment & Information GmbH.
- 12
13 80. Margraf, J., et al., *DIPS Open Access: Diagnostic Interview for Mental Disorders. [DIPS Open Access: Diagnostisches Interview bei psychischen Störungen.]* 2017, Bochum: Mental Health Research and Treatment Center, Ruhr-Universität Bochum.
- 14
15
16 81. Bifulco, A., et al., *Adult attachment style. I: Its relationship to clinical depression*. 2002. **37**(2): p. 50-59.
- 17
18 82. Bergant, A., et al., *Deutschsprachige Fassung und Validierung der» Edinburgh postnatal depression scale «*. DMW-Deutsche Medizinische Wochenschrift, 1998. **123**(03): p. 35-40.
- 19
20 83. Ehlers, A., J. Margraf, and D. Chambless, *Fragebogen zu körperbezogenen Ängsten, Kognitionen und Vermeidung (AKV)*. 2001, Göttingen: Beltz Test.
- 21
22 84. Lips, H.M. and K. Bloom, *Psychometric Evaluation of a New Scale to Measure Maternal Self-Confidence*. 1993: Radford.
- 23
24 85. Parker, G., H. Tupling, and L.B. Brown, *A Parental Bonding Instrument*. British Journal of Medical Psychology, 1979. **52**(1): p. 1-10.
- 25
26 86. Schumacher, J., M. Eisemann, and E. Brähler, *Fragebogen zum erinnerten elterlichen Erziehungsverhalten*. 2000: Huber.
- 27
28 87. Ehrenthal, J., et al., *Evaluation der deutschsprachigen Version des bindungsfragebogens 'Experiences in Close Relationships-Revised' (ECR-RD)*. Psychotherapie Psychosomatik Medizinische Psychologie, 2009. **59**(6): p. 215-223.
- 29
30 88. Fydrich, T., G. Sommer, and E. Brähler, *Fragebogen zur Sozialen Unterstützung (F-SozU). Manual*. Göttingen: Hogrefe.
- 31
32 89. Zimmermann, J., et al., *The structure and correlates of self-reported DSM-5 maladaptive personality traits: Findings from two German-speaking samples*. . Journal of Personality Disorders, 2014. **28**(4).
- 33
34 90. Klinitzke, G., et al., *[The German Version of the Childhood Trauma Questionnaire (CTQ): psychometric characteristics in a representative sample of the general population]*. Psychother Psychosom Med Psychol, 2012. **62**(2): p. 47-51.
- 35
36 91. Hahlweg, K., *Fragebogen zur Partnerschaftsdiagnostik*. 1996, Göttingen: Hogrefe.
- 37
38 92. Bodenmann, G., *Dyadisches coping inventar: Testmanual [Dyadic coping inventory: Test manual]*. Bern, Switzerland: Huber, 2008.
- 39
40 93. Tröster, H., *Eltern-Belastungs-Inventar (EBI). Deutsche Version des Parenting Stress Index (PSI) von R. R. Abidin*. 2010: Manual Göttingen: Hogrefe.
- 41
42 94. Bifulco, A., et al., *The Vulnerable Attachment Style Questionnaire (VASQ): an interview-based measure of attachment styles that predict depressive disorder*. Psychological Medicine, 2003. **33**(6): p. 1099-1110.
- 43
44 95. Oldfield, R.C., *The assessment and analysis of handedness: The Edinburgh inventory*. Neuropsychologia, 1971. **9**(1): p. 97-113.
- 45
46 96. Pauli-Pott, U., B. Mertesacker, and D. Beckmann, *Ein Fragebogen zur Erfassung des «frühkindlichen Temperaments» im Elternurteil*. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 2003. **31**(2): p. 99-110.
- 47
48 97. Martin-Soelch, C., et al., *Reduced response to reward in smokers and cannabis users*. Neuropsychobiology, 2009. **60**(2): p. 94-103.
- 49
50 98. Scheele, D., et al., *Oxytocin enhances brain reward system responses in men viewing the face of their female partner*. Proceedings of the National Academy of Sciences, 2013. **110**(50): p. 20308-20313.
- 51
52 99. Schwartz, E.P., et al., *Assessing salivary cortisol in studies of child development*. Child Development, 1998. **69**(6): p. 1503-1513.
- 53
54 100. Feldman, R., *Coding interactive behavior manual*. 1998, Unpublished Manual; Bar-Ilan University, Israel.
- 55
56
57
58
59
60

Eckstein et al NEMO study protocol

101. Feldman, R., S. Masalha, and R. Nadam, *Cultural perspective on work and family: dual-earner Israeli-Jewish and Arab families at the transition to parenthood*. J Fam Psychol, 2001. **15**(3): p. 492-509.
102. Pruessner, J.C., et al., *Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change*. Psychoneuroendocrinology, 2003. **28**(7): p. 916-931.
103. Stalder, T., et al., *Assessment of the cortisol awakening response: Summary of the ISPNE expert consensus guidelines*. Psychoneuroendocrinology, 2016. **71**: p. 44.
104. Feldman, R. and S. Masalha, *Parent-child and triadic antecedents of children's social competence: Cultural specificity, shared process*. Developmental Psychology, 2010. **46**(2): p. 455.
105. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Administration Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
106. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Technical Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
107. Albers, C.A. and A.J. Grieve, *Test review: Bayley, N.(2006). Bayley scales of infant and toddler development-third edition*. San Antonio, TX: Harcourt assessment. Journal of Psychoeducational Assessment, 2007. **25**(2): p. 180-190.
108. Reck, C., et al., *Maternal avoidance, anxiety cognitions and interactive behaviour predicts infant development at 12 months in the context of anxiety disorders in the postpartum period*. Infant Behavior and Development, 2018. **50**: p. 116-131.
109. Brett, M., et al. *Region of interest analysis using an SPM toolbox*. in *8th international conference on functional mapping of the human brain*. 2002. Sendai.
110. Gerchen, M.F., et al., *The SyBil-AA real-time fMRI neurofeedback study: protocol of a single-blind randomized controlled trial in alcohol use disorder*. BMC Psychiatry, 2018. **18**(1): p. 12.

AUTHORS' CONTRIBUTION STATEMENT:

B.D., P.K., A.-L.Z. and M.E. designed the study; M.E. and A.-L.Z. lead the study; S.A.J. collected data; P.K., M.F.G. and M.M.S. established the experimental set-up; S.A.J., A.-L.Z. and ME wrote the manuscript; All authors provided comments on the manuscript.

ACKNOWLEDGEMENTS:

The authors wish to thank Britta Zipser, Ekaterina Schneider, Madgalena Vragovic, Elena Augenstein, Johanna Jübner, Antonia Hüge, Corinna Abdaoui, Nora Nonnenmacher, Nina Schlegel, Josephine Parol, Lydia Oeljeklaus and Hanna-Sophie Lässig for their assistance with conducting the study.

FUNDING STATEMENT:

This work was supported by the Dietmar-Hopp Foundation (September 2017- March 2020). The funding agency had no role in the planning of the study design and will not be involved in data collection, analysis, decision to publish or preparation of the manuscript.


COMPETING INTERESTS STATEMENT:

The authors declare that they have no competing interests.




When Needed:
Neurofeedback-Training
3 Sessions, at intervals of
circa 14 days

BMJ Open



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	23
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	23
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	23

1	sponsor contact		
2	information		
3			
4	Roles and	#5c	
5	responsibilities:		
6	sponsor and funder		
7		Role of study sponsor and funders, if any, in study design;	
8		collection, management, analysis, and interpretation of	
9		data; writing of the report; and the decision to submit the	
10		report for publication, including whether they will have	
11		ultimate authority over any of these activities	
12	Roles and	#5d	
13	responsibilities:		
14	committees		
15		Composition, roles, and responsibilities of the coordinating	
16		centre, steering committee, endpoint adjudication	
17		committee, data management team, and other individuals or	
18		groups overseeing the trial, if applicable (see Item 21a for	
19		data monitoring committee)	
20	Background and	#6a	
21	rationale		4-7
22		Description of research question and justification for	
23		undertaking the trial, including summary of relevant studies	
24		(published and unpublished) examining benefits and harms	
25		for each intervention	
26			
27	Background and	#6b	
28	rationale: choice of		7
29	comparators		
30		Explanation for choice of comparators	
31			
32	Objectives	#7	
33			7
34		Specific objectives or hypotheses	
35	Trial design	#8	
36			7
37		Description of trial design including type of trial (eg, parallel	
38		group, crossover, factorial, single group), allocation ratio,	
39		and framework (eg, superiority, equivalence, non-inferiority,	
40		exploratory)	
41			
42	Study setting	#9	
43			14
44		Description of study settings (eg, community clinic,	
45		academic hospital) and list of countries where data will be	
46		collected. Reference to where list of study sites can be	
47		obtained	
48	Eligibility criteria	#10	
49			9
50		Inclusion and exclusion criteria for participants. If applicable,	
51		eligibility criteria for study centres and individuals who will	
52		perform the interventions (eg, surgeons, psychotherapists)	
53			
54	Interventions:	#11a	
55	description		9-10
56			
57		Interventions for each group with sufficient detail to allow	
58		replication, including how and when they will be	
59		administered	
60			

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-14
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	10
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	10
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	9
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	9
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	10
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	15
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	15
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	2
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	23
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

and disclosure of contractual agreements that limit such access for investigators

1			
2			
3			
4	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for
5	trial care		compensation to those who suffer harm from trial
6			participation
7			
8			
9	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial
10	trial results		results to participants, healthcare professionals, the public,
11			and other relevant groups (eg, via publication, reporting in
12			results databases, or other data sharing arrangements),
13			including any publication restrictions
14			
15			
16			
17	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of
18	authorship		professional writers
19			
20			
21	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,
22	reproducible		participant-level dataset, and statistical code
23	research		
24			
25			
26			
27	Informed consent	#32	Model consent form and other related documentation given
28	materials		to participants and authorised surrogates
29			
30			
31	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of
32			biological specimens for genetic or molecular analysis in the
33			current trial and for future use in ancillary studies, if
34			applicable
35			
36			

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027747.R2
Article Type:	Protocol
Date Submitted by the Author:	22-Mar-2019
Complete List of Authors:	Eckstein, Monika; UniversitätsKlinikum Heidelberg, Zietlow, Anna-Lena; UniversitätsKlinikum Heidelberg, Institute for Medical Psychology Gerchen, Martin; Central Institute for Mental Health, Department of Clinical Psychology Schmitgen, Mike; UniversitätsKlinikum Heidelberg, Department of General Psychiatry Ashcroft-Jones, Sarah; UniversitätsKlinikum Heidelberg Kirsch, Peter; Central Institute for Mental Health, Department of Clinical Psychology; Bernstein Center for Computational Neuroscience Ditzen, Beate; UniversitätsKlinikum Heidelberg, Institute of Medical Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Radiology and imaging
Keywords:	mother-infant bonding, maternal bonding difficulties, ventral striatum, oxytocin, functional magnetic resonance imaging (fMRI) neurofeedback, dopamine

SCHOLARONE™
Manuscripts

Eckstein et al NEMO study protocol

The NeMo Real-Time fMRI Neurofeedback Study: Protocol of a Randomised Controlled Clinical Intervention Trial in the Neural Foundations of Mother-Infant-Bonding

*Monika Eckstein¹, *Anna-Lena Zietlow¹, Martin Fungisai Gerchen^{2,3}, Mike Michael Schmitgen⁴, Sarah Ashcroft-Jones¹, Peter Kirsch^{2,3}, Beate Ditzen¹

¹Institute of Medical Psychology, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

²Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany.

³Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.

⁴Department of General Psychiatry, Centre of Psychosocial Medicine, University Hospital, Heidelberg University, Germany.

* contributed equally to this paper

Key words: mother-infant bonding, maternal bonding difficulties, ventral striatum, functional magnetic resonance imaging (fMRI) neurofeedback, oxytocin, dopamine

Word Count (Excluding title page, abstract, references, figures and tables): 5915

*Corresponding Authors:

Monika Eckstein and Anna-Lena Zietlow

Institute of Medical Psychology,

Centre for Psychosocial Medicine,

Heidelberg University Hospital, Heidelberg University,

Bergheimer Str. 20,

69115 Heidelberg,

Germany

Email: monika.eckstein@med.uni-heidelberg.de

anna-lena.zietlow@med.uni-heidelberg.de

Tel: +49 (0) 2221 56-7871

Eckstein et al NEMO study protocol

ABSTRACT:

Introduction:

Most mothers feel an immediate, strong emotional bond with their new-born. On a neurobiological level, this is accompanied with the activation of the brain reward systems, including the striatum. However, approximately 10% of all mothers report difficulties to bond emotionally with their infant and display impaired reward responses to the interaction with their infant which might have long-term negative effects for the child's development.

As previous studies suggest that activation of the striatal reward system can be regulated through Functional Magnetic Resonance Imaging (fMRI) based Neurofeedback (NFB), we have designed and investigate fMRI-NFB training to treat maternal bonding difficulties.

Methods and analysis:

In the planned trial, mothers will be presented pictures of their infant and real-time fMRI, peripheral measures, neural, endocrine, psychophysiological and behavioural measures will be assessed. Mothers with bonding difficulties (N= 68) will be randomised to one of two double blind intervention groups at 4-6 months postpartum. They will participate in three repeated neurofeedback training sessions with rtfMRI NFB training to increase activation of a) the ventral striatum or b) the anterior cingulate. Interview data and real-time mother-infant interaction behaviour pre-, post-intervention and at follow-up will serve as clinical outcome measures.

Ethics and Dissemination:

Study procedures are in line with the recommendations of the World Medical Association (revised Declaration of Helsinki) and were approved by the Ethics Committee of the Medical Faculty, s-450/2017, Heidelberg University. All participants will provide written informed consent after receiving a detailed oral and written explanation of all procedures and can withdraw their consent at any time without negative consequence.

Results will be internationally published and disseminated, to further the discussion on non-pharmacological treatment options in complex mental disorders.

Trial registration details:

The study is registered in the German Register for Clinical Trials (DRKS) DRKS00014570.

Eckstein et al NEMO study protocol

ARTICLE SUMMARY:

Strengths and Limitations of this Study:

- The novelty of used methods allow the investigation of the effect of real-time Functional Magnetic Imaging (rtfMRI) neurofeedback (NFB), on maternal bonding.
- The study investigates the ability of rtfMRI NFB to upregulate brain activity in correlation with behavioural and biopsychological markers.
- The simultaneous investigation of two brain regions as well as the presence of a control group proposed in the methods of this protocol enables a comparative analysis of the benefits of the rtfMRI training, as well as increasing clarity regarding the role of differential brain regions in social reward.
- The proposed method, through its' longitudinal design with follow-up measures, will help to evidence how neurofeedback training brings about behavioural change, in turn allowing for better understanding of the potential applications, predictive neural signatures and participant criteria crucial for the success of rtfMRI.
- Due to the statistical co-occurrence of maternal bonding difficulties and postpartum depression and the similar pattern of muted reward responses in both instances, the explanatory power of the results of the rtfMRI NFB intervention may be confounded.

INTRODUCTION:

The Neurobiological, Emotional and Behavioural Aspects of Maternal Bonding:

The parental bond is the first social bond that infants experience in life. Usually, it is the mother who serves as the child's immediate and most central social interaction partner. Maternal bonding is reflective of the first emotional bond that a mother gradually develops with her infant, within the first weeks postpartum, and is characterized by positive feelings, emotional warmth and affection towards the infant,[1]. In the eyes of some researchers, maternal bonding represents one of the most important psychological processes that gradually unfold after birth,[2] and is a significant and central aspect of the emerging relationship between mother and infant,[3].

The initial period after birth is also known as the "Baby-Honeymoon", a state of euphoria and happiness fuelled by the desire to constantly be near and to "fall in love" with the infant, which allows the mother to take on the challenges of the adaptation to parenthood. In this way, maternal bonding also fulfils a biological function by ensuring the care for and subsequent survival of the new-born,[4]. On the behavioural level maternal bonding emerges through touch, eye-contact, use of "motherese", and the smiling at or caressing of the infant,[5]. Maternal bonding can therefore be said to be expressed in the caregiving behaviours of the parent, in their focus on and high level of sensitivity to the needs of the infant,[6]. On the other hand, maternal bonding is also formed in the mother's emotions and thoughts about the infant and in the mental representations of motherhood that the mother holds,[7].

The strength of maternal bonding can also be demonstrated on a neurobiological level,[8]. Central structures such as the striatum, ventral tegmental area, amygdala, septum and hypothalamus are involved in affiliative behaviour, together with a combination of neurotransmitters and modulators such as dopamine and oxytocin[9, 10]. For affiliative traits, it has been proposed that those are mediated by dopaminergic projections from the ventral tegmental area and endogenous opioids in the hypothalamus with projections to the septum, especially during physical contact [11], that underlie rewarding feelings of affiliation.

One finding of central relevance to maternal bonding in particular is that mothers who report a good emotional bonding to their infant show increased reward-related activation in dopaminergic brain regions (the nucleus accumbens in the ventral striatum) in response to infant stimuli,[12]. These effects are particularly evident in the mother, in comparison to other caregivers, and have been assumed to be reinforced through the hormonal changes that accompany both birth and breast-feeding behaviours,[13, 14].

However, the bonding process is not always successful,[15, 16] and impaired maternal bonding can lead to avoidance or ambivalent emotions or behaviour in the mother. Impaired bonding can result not only in a lack of affection but also, in extreme cases, in the immediate rejection or neglect of the infant, as well as the possible presence of hostility or aggressive impulses,[2, 7]. Although postpartum bonding difficulties also occur in psychologically healthy mothers, they are observed particularly in the context of postpartum depression,[17, 18]. In a representative German sample 6.4% of psychologically healthy mothers reported difficulties in establishing emotional bonding with their infant. In depressed mothers the rate of prevalence is significantly higher at 17-29%,[19]. Furthermore, it has been shown that even subclinical depressive symptoms may negatively affect the developing bonding during the first months postpartum,[20].

Depression during the postpartum period itself is generally characterised by loss of interest or joylessness, insomnia, feelings of guilt, difficulties concentrating and, in severe cases, suicidal tendencies. Intense feelings and self-blame about being a bad mother are also often reported,[21]. On a neurobiological level, postpartum depression relates to a reduced level of reactivity in the striatal reward system, for example in the putamen,[22], but also the amygdala network [23] together with endocrine changes in the serotonin and steroid systems [24]. Studies show that in particular the mother-infant relationship,[25, 26], as well as the actual

Eckstein et al NEMO study protocol

1
2
3 mother-infant interaction,[27], both short and long-term can be impaired by peri- and
4 postpartum depression,[25, 28]. Results of a recent study suggest that the link between
5 maternal depressive symptoms at 2 months postpartum and maternal report about interaction
6 with the infant at 6 months was mediated by maternal feelings of attachment,[29]. The present
7 study focuses on bonding impairments, rather than postpartum depression, although there will
8 be inevitable co-occurrence in the participant sample.
9

10
11 Research indicates that experiences and interaction in the “sensitive” postpartum
12 period have long term consequences for the cognitive as well as socio-emotional development
13 in children,[25, 30]. Animal studies have also demonstrated that positive caring behaviours of
14 the mother positively influence offspring brain development and long-term stress-coping
15 behaviours even in the next generation via epigenetic changes,[31]. Conversely, in humans,
16 decreased maternal bonding can result in higher rates of self-directed affect regulation
17 strategies and increased stress-reactivity [32] of the infant, as well as variable self-comfort
18 behaviours, moderated by the infant’s gender and age,[32]. Research also indicates that
19 restrained (distant) maternal behaviour can have far-reaching negative consequences for self-
20 regulation, social behaviour and stress management in the infant [25, 30], even into adulthood
21 with potential influences on own parenting behaviour,[33]. Furthermore, the association
22 between maternal depression, anxiety disorders and stress-reactivity with changes in the
23 hypothalamic-pituitary-adrenocortical axis (HPA axis) is well-documented,[34]. Indeed, recent
24 studies indicate that infant exposure to maternal mental disorders can increase infant baseline
25 cortisol levels, as the main outcome of the HPA axis, in the case of maternal depression and
26 increase infant cortisol reactivity in cases of maternal anxiety,[35]. In a lower income setting,
27 exposure to variable intensities of maternal depression demonstrated a U-shaped response
28 curve in infant cortisol reactivity levels in the context of immunisation. Those with exposure to
29 moderate-maternal depression levels demonstrated the lowest cortisol reactivity during
30 immunisation,[36]. The importance of the influence of maternal interaction behaviours
31 themselves is also clear. One particular study demonstrates, for example, that maternal
32 sensitivity during the interaction with their infant has a moderating influence between maternal
33 mental health during pregnancy and infant salivary cortisol levels,[37]. Given data on the
34 transgenerational transmission of maternal care via epigenetics,[38], both in maternal-infant
35 bonding,[39-41] and care-giving behaviours,[42] the importance of effective treatment and
36 intervention plans are evident.
37

38
39 Current inpatient and outpatient mother-infant therapies, established in the context of
40 postpartum mental disorders, focus not only on the disorder-specific treatment but also on
41 specific elements for the promotion of the mother-infant relationship (e.g. baby massage and
42 video feedback methods). Video feedback interventions have been shown to have a positive
43 influence on mother-infant interaction,[43, 44] as well as the maternal self-efficacy in
44 interacting and coping with the infant,[45, 46]. To our knowledge, maternal bonding has thus
45 far only been recorded as an outcome variable in one study using video feedback
46 invention,[47]. This intervention demonstrated improvements in maternal bonding; however,
47 the participant pool only included mentally healthy women without postpartum bonding
48 problems. Thus, interventions focussing on maternal bonding in women experiencing
49 difficulties forming an emotional bond to their infant are urgently needed. Presently, such
50 interventions or findings, directly relating maternal bonding difficulties and their effects on the
51 infant’s stress reactivity in either biological or behavioural domains, are still lacking and in
52 particular non-pharmacological treatment concepts would substantially broaden the treatment
53 options for affected mothers and their infants.
54
55

56 **Reward Learning in Depression and its Relation to Postpartum Bonding Difficulties:**

57 On a neural level the dopamine-mediated reward system (specifically the ventral striatum and
58 the nucleus accumbens) is crucial to the rewarding aspects of social interaction,[48, 49]. The
59 ventral striatum also appears to be specifically involved in learning rewarding stimuli, where
60

1
2
3 high neural activation, correlated with the "BOLD response" in the fMRI, is accompanied by
4 an increased dopaminergic response,[48]. As part of the learning process this reward
5 activation is first triggered by primary enhancers, such as glucose, and over the course of the
6 learning process transfers to secondary enhancers, such as food or money. In humans, from
7 early in life, repeated positive social experiences can be seen as very strong reward and
8 provided the basis for the much discussed "social brain hypothesis", in brain research [50, 51].
9

10 Images of happy children are generally perceived as positive by healthy individuals
11 and activate the striatal areas of the brain,[52]. Psychologically healthy mothers also show a
12 differential neural activation response to visual stimuli of happy children, as compared with
13 stimuli of more ambiguous facial expressions of children. Expressions of joy activated the right
14 limbic and paralimbic areas, by comparison ambiguous expressions correlated to activity in
15 the left higher cognitive and motor areas that are often linked to cognitive effort,[53].
16 Consequently, positively reinforcing activities that lead to such activation, i.e. positive social
17 interaction, are likely to be subsequently performed more frequently. In the case of the
18 presence of depressive symptoms, however, such neural activation (i.e. activation in striatal
19 and limbic networks) seems to be diminished during positive social interactions, these
20 activities are therefore perceived as less rewarding,[54, 55] and diminish the motivation for
21 social contact. Mothers with depressive symptoms demonstrated reduced activation in
22 subcortical and cortical limbic regions (amygdala, cingulate) and cortical regions involved in
23 emotion regulation (including the frontal cortex, insula, anterior cingulate); in line with
24 symptomology of diminished capacities to experience joy and to down-regulate anger, anxiety,
25 or worry,[22, 23, 56]. Notably mothers with postpartum depression show a reduced activation
26 in striatal reward areas in response to stimuli of their own children,[22, 23, 56].
27

28 On a neuroendocrine level, basic research suggests that in rodents social-interaction
29 related reward is associated with receptor-activation for the neuropeptide oxytocin in the
30 nucleus accumbens,[57]. Initial data in humans indicates, that methylation of the oxytocin
31 receptor gene is associated with attachment in different phases of the individual's lifespan,[58]
32 and higher methylation is associated with postpartum depression,[59]. Antidepressant
33 treatment, in turn, is assumed to lower methylation,[60]. This may explain, on a neurobiological
34 level. the correlation between postpartum depression and maternal bonding difficulties,[61].
35 However, no contemporary intervention has yet focussed on the perception of the mother-
36 infant interaction in terms of reward and involved oxytocin-related outcomes as possible
37 evaluation criteria.
38

39 40 41 42 **rtfMRI NFB as a Treatment Method:** 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Eckstein et al NEMO study protocol

1
2
3 Neurofeedback (NFB) is a novel method which, through the visualization of real-time brain
4 activation, allows an individual to consciously regulate one's own brain activation. While it is
5 well-established that mental strategies modulate brain activation as measured by fMRI blood
6 oxygen level dependent signal (BOLD), NFB asks participants to modulate activation in
7 prescribed regions or even networks of their brain by their own volition and in response to the
8 immediate feedback/ visualization of the related brain activation patterns,[62]. Thus,
9 volunteers can learn to regulate the activation of a previously defined brain region (see,[63]
10 for a review). NFB interventions have previously often used electroencephalography (EEG)
11 and other electrophysiological methods to visualize and modulate activation in higher-cortical
12 areas. However, smaller and deeper areas of the limbic and reward system can be imaged
13 primarily with high-resolution magnetic resonance imaging (MRI). One previous study has
14 proven that healthy volunteers can be trained to voluntarily increase their brain activation
15 patterns that have been classified for affiliative emotions in the same individual subject using
16 voxel pattern analyses [64]. From a therapeutic point of view, the targeted modulation of
17 specific brain areas and associated circuits via neurofeedback should be associated with the
18 improvement of mental symptoms.
19

20
21 In initial clinical pilot studies, for example, patients with borderline personality disorder,
22 anxiety or obsessive-compulsive disorders have shown the ability to down regulate activation
23 in the insula or the hyperactive amygdala in response to stress-related stimuli,[65-67].
24 Similarly, high risk alcohol consumers learned to down regulate the reward related activation
25 of alcohol related stimuli,[68]. In PTSD patients, the changes in brain connectivity after fMRI
26 neurofeedback correlate with the reduction of symptoms,[69]. Based on the previously
27 articulated and evidenced notion of the psychobiological mechanisms underlying attachment
28 and bonding as goal-oriented and reward-drive,[70], the proposed study looks to investigate
29 whether specific activation of the ventral striatum can be voluntarily increased through training
30 in the context of mother-infant bonding. Indeed in previous research, patients with major
31 depressive disorders or schizophrenia were successfully trained to increase the activation of
32 the hypoactive amygdala and the anterior cingulum in conjunction with positive stimuli,[71,
33 72]. Therefore, in line with the current understanding and treatment of mental illnesses, rtfMRI
34 NFB represents a promising new intervention method for complex mental processes.
35 Particularly important for understanding the potential of rtfMRI interventions is the transfer of
36 the modulation of the BOLD signal towards behavioural changes,[62] which allows the value
37 of this intervention form in a clinical setting to be distilled.
38
39
40

41 **The Planned Trial:**

42 In the planned double-blind randomized intervention trial (the "Neurofeedback for Mothers with
43 Postpartum Bonding Difficulties Study", "NeMo-Study"), three central points will be addressed.
44

- 45 1. Women with postpartum bonding difficulties (including women with postpartum
46 depression) will be compared to healthy unaffected women in terms of reward-related
47 brain activation to pictures showing their own infant and control stimuli. It is
48 hypothesized that women with bonding difficulties show less brain response in the
49 reward-related areas (ventral striatum) compared to the control group.
50
- 51 2. The clinical group will then undergo a regiment of NFB training. Participants will learn
52 to consciously increase the activation of reward-associated brain areas (specifically
53 the ventral striatum), or a control region (anterior cingulate cortex, ACC), during the
54 presentation of images of their own infant. For ethical reasons, an active control
55 treatment was chosen rather than joke or non-feedback. The activation of the central
56 nervous dopamine system via the striatum is hypothesized to improve bonding
57 motivation and social interaction behaviour. The coupling of infant stimuli to the central
58 nervous reward activation should make it easier for these women to feel more joy in
59 the real interaction,[62] with their infant post-training and to be more attentive and more
60

sensitive in their interactions. Training of the dorsal/rostral ACC with a rather unspecific role in emotion regulation, such as e.g. in cognitive reappraisal,[73] or response inhibition [74], may have general beneficial effects as shown in another NFB study [71] but also indirectly influence parental affect regulation,. However, the more specific striatal feedback based on the rewarding aspects of the mother-child interaction are assumed to have stronger effects.

3. Effects of the NFB training will be related to the changes in behaviourally coded mother-infant interaction, maternal bonding quality and diagnostics, and epigenetic oxytocin receptor alterations, as assessed from peripheral blood. It is hypothesized that following the ventral striatum intervention, interaction, maternal bonding, and epigenetic markers will approximate the values of the healthy control group.

Thus, the study will address reward-related processes in impaired maternal bonding, observable changes on a behavioural and neuroendocrine level post-training - important steps in illustrating the validity of rtfMRI NFB as an intervention method,[62]. The proposed study is therefore well placed to produce a wealth of valuable and informative data, both regarding the potential scope of rtfMRI as a non-pharmacological intervention to young mothers.

METHODS AND ANALYSIS:

Design Overview:

To investigate points 1) – 3) (above) a controlled longitudinal study with randomised allocation of the two intervention groups to one of two anatomically defined regionally targeted areas in the NFB training will be employed. The two intervention groups will consist of mothers with identified maternal-bonding difficulties, while the control group will consist of psychologically-healthy mothers without bonding difficulties. The intervention groups will receive three NFB training sessions at intervals of approximately 14 days. Changes in maternal behaviours during mother-infant-interaction, measured using standardised coding of behavioural observations, will be assessed as the primary outcome measure. Possible alterations in oxytocin receptor methylation and gene expression will serve as secondary outcome measures. See Figure 1 for overview of study design and timeline (Figure 1).

[Figure 1: Overview of Study Design around here]

Participant Eligibility and Recruitment:

Eligible Participants:

Intervention Group: Mothers who report postpartum bonding difficulties, may present with a wide range of depressive symptoms.

Control Group: Psychologically healthy mothers with intact bonding to child.

Exclusion Criteria for all Groups:

Mothers: acute suicidality, bipolar or schizophrenic disorders, diagnosed dementia or substance abuse or substance dependency. Necessary fMRI exclusion criteria also apply.

Infants: multiple birth infants, preterm birth, confirmed physical or developmental disorders, which make participation impossible or unwise.

Participant Recruitment:

Eckstein et al NEMO study protocol

Participants will be recruited both online and by flyers disseminated through midwives, gynaecologists, paediatricians, in pharmacies and in maternity hospitals as well as mothering forums or self-help groups (e.g. "Shadow and Light ") and registration offices. They receive thorough information about the study procedures both orally and in written form. The volunteer recruitment structure of the study makes it possible that given the intense feelings of self-blame symptomatic of the often co-occurring postpartum depression,[18] those most severely affected may not volunteer for the study. This limitation will be addressed via carefully worded and emphatic recruitment materials and processes.

Patient and Public Involvement

Patients and the general public were not involved in the design or implementation of this study. However, the participants are asked to report on the cognitive strategies they adopted during their rtfMRI NFB sessions and their subjective success with those strategies. These findings may inform future formulations of patient based NFB interventions.

The results of this study will not be disseminated to the participants directly but will be openly accessible online.

Screening assessment and group allocation:

Screening Assessment:

For inclusion in the study all potential participants will be screened (T0) prior to inclusion.

Random Group Assignment Procedure:

True random assignment to the two clinical intervention groups or the control group cannot occur due to the quasi-experimental nature of the design: The mothers are assigned to being clinical or control based on the quality of their postpartum bonding to their infant. Inclusion as part of the clinical intervention group is based on the categorical assessment of impaired maternal bonding using an in-depth interview based on the proposed criteria by,[19] and asked during the clinical interview. This approach additionally allows for the dimensional assessment of maternal-bonding impairments. Bonding assessment is further elaborated by the use of additional questionnaires exploring bonding impairment, such as the Postpartum Bonding Questionnaire 16 (PBQ-16), which holds an internal consistency of Cronbach's $\alpha=0.085$,[5].

Within the intervention group participants will be completely randomly and automatically assigned to one of the following two conditions: NFB of the right ventral striatum (clinical intervention group I) or NFB of the right anterior cingulate cortex (ACC) (clinical intervention group II). This randomisation is based on the order of inclusion into the study and pre-assigned lists that are double-blind in nature using nonpublic lists made by a colleague not involved in assessments and analyses. During all three intervention sessions, participants will be trained to modulate activation of the same pre-defined brain region (right ventral striatum or right ACC) based on the functional tasks during T1. Blinding of the treatment group will be revealed after the analyses at group level.

Power Analysis and Size Estimation:

The program G-Power v.3.1.9.2,[75] was used, in order to calculate the required sample size. To test the hypotheses mentioned above, a total of approximately $N = 100$ cases is estimated.

To perform a simple group comparison of maternal sensitivity between two treatment groups with a middle to large effect size ($d = 0.78$),[44] with a power of 90% and an alpha-error threshold of $p = .05$, a minimum group size of $N = 30$ for each clinical intervention group

Eckstein et al NEMO study protocol

is required (I, NFB of the ventral striatum, II, NFB of the ACC). Assuming a drop-out rate of approx. 10%, an experimental sample of N = 100 will be aimed for in the projected study. With a repeated measures analyses and the T3 (follow-up) measurement the power is improved, which makes it possible to observe even medium effects with this planned sample.

N = 68 mothers with postpartum bonding difficulties will be included in the intervention (N = 34 to NFB region I ventral striatum, N = 34 to NFB region II ACC). Mental disorders, and especially postpartum depressive symptomatology, are measured in a multi-dimensional fashion through a structured clinical interview and a validated peri-partum period questionnaire. Variability in depressive symptoms, ranging from none to moderate symptom-load is sought, thus allowing for appropriate and adequate statistical analysis of this covariate factor. As a control group N = 32 psychologically healthy women with a good bond with their infant will be recruited.

Pre- Post and Follow-Up Assessments (T1, T2 and T3):

Before (T1) and after the training (T2), participants will perform an extensive battery of diagnostic assessments characterizing the clinical aspects of bonding, including the instructed mother-child-interaction in the Face-To-Face-Still-Face-Paradigm,[76, 77]. A baseline fMRI session will assess the sensitivity of both the reward system and the limbic system using established fMRI tasks and blood samples will be collected for analysing hormonal and (epi-)genetic markers. After the end of the last neurofeedback training a post-intervention measurement (T2) and with 12 month a follow up (T3) will be performed using the same methods as at T1. At T3, mothers and infants will be instructed to freely play,[78] and videotaped. Age-specific markers of the infant's development will be coded using a standardized developmental test,[79]. (Refer to Figure 1 for timeline clarification).

This combination of assessments allows for a comprehensive understanding of maternal bonding and behaviour on a neural, neuroendocrine, epigenetic and behavioural level.

The primary behavioural outcome measures includes the quality of maternal-infant interaction behavior (composite scores of maternal and dyadic behavior) while on the neuronal level, we assess the BOLD response to positive stimuli of the child as primary outcome measure. Physiological, endocrine and genetic markers serve as secondary outcomes.

See Table 1 for further details on the assessments and scheduling of measure collection.

Survey instruments and Coding Systems used in the Study:

Measure	Citation	M.	F.	I.	T0	T1	N	T2	T3
Mother and infant:									
Mother-Infant Interaction (FFSF)	[76, 77]	X		X		X		X	
Free-Play Situation	[78]	X		X					X
Interviews:									
Diagnostic Interview for Mental Disorders	[80]	X							
Interview for Postpartum Bonding Difficulties		X	X						
Attachment Style Interview	[81]	X	X						
Questionnaires:									
Postpartum Bonding Questionnaire 16-R	[5]	X	X			X		X	X

Eckstein et al NEMO study protocol

Edinburgh Postnatal Depression Scale	[82]	X	X		X	X	X
Agoraphobic Cognitions Questionnaire, Body Sensations Questionnaire, and Mobility Inventory	[83]	X	X		X	X	X
Maternal Self-Confidence Scale	[84]	X	X		X		X
Prenatal Emotional Stress Index	[17]	X	X				
Parental Bonding Instrument	[85]	X	X		X		
German version of the EMBU questionnaire regarding remembered parenting behaviours	[86]	X	X		X		
Experiences in Close Relationships- Revised	[87]	X	X		X		
Social Support Questionnaire	[88]	X	X		X	X	X
Personality Inventory- DSM 5 Short Form	[89]	X	X		X		
Childhood Trauma Questionnaire	[90]	X	X		X		
Partnership Questionnaire	[91]	X	X		X	X	X
Dyadic Coping Inventory	[92]				X	X	X
Parenting Stress Inventory	[93]	X	X			X	X
Vulnerable Attachment Style Questionnaire	[94]	X	X		X		
Edinburgh Handedness Questionnaire	[95]						X
Infant:							
Infant Behaviour Questionnaire	[96]	X	X		X		X
Development Assessment: Infant							
Bayley's Infant Development Scale III	[79]			X			X
Physiological Measures							
Infant Saliva Sample				X	X	X	X
Mother Blood Sample		X			X	X	X
Neurofeedback Training							
Reward Task	[97]	X			X	X	X
Emotional Go-No-Go	[74]	X			X	X	X
Passive Viewing Task	[98]	X			X	X	X

Table 1: Schedule of measures used the in study. M. Mother Response, F. Father response, I. Infant response, T0 screening assessment, T1 baseline assessment, N-neurofeedback sessions, T2 post assessment, T3 follow-up.

Detailed Description of Measures, Methods and Instruments used:

Initial Assessments:

Baseline Assessment:

For the baseline testing period (T1) the mothers will be invited to our video-laboratory together with their infants. A structured clinical interview according to DSM-5 as well as an interview regarding postpartum bonding difficulties will be carried out. Subsequently, parent-infant interaction will be assessed and videotaped during the Face-to-Face-Still-Face (FFSF) paradigm, a widely used paradigm for evaluating the quality of early parent-infant interaction,[76]. To determine infant stress-reactivity, cortisol and alpha-amylase will be extracted from infant saliva according to standard protocols,[99], which is collected before (C1), immediately after (C2), 20 minutes (C3) and 30 minutes after the FFSF (C4).

Eckstein et al NEMO study protocol

Instructed Mother-infant interaction:

Mother-infant-interaction pre- post-intervention (T1 and T3): The standardised mother-infant-interaction before and after the intervention follows the established FFSF paradigm,[76, 77]. It consists of three consecutive instructed two-minute episodes in which the mother, with the infant seated in the baby chair, interacts in accordance with a fixed pattern: First, an initial face-to-face interaction in which the mothers are instructed to play with their infant as usual (without the aid of toys and pacifiers). Next, the still-face episode in which the mothers have to turn their head aside while silently counting to ten and then turn back to the infant but not engage in any gestures, facial expressions, or vocalizations. Finally, the procedure ends with the reunion episode in which the mother is required to resume face-to-face play with her infant.

Mother-infant-interaction Follow-Up (T4): As the Still-face paradigm can be conducted up to the age of 9 months, parent-infant interaction will be assessed at T4 during a 15-minute free-play situation and a subsequent limit setting task. All interaction episodes will be videotaped and coded according to the Coding Infant Behaviour Scales (CIB),[100]. The CIB scales assess parental sensitivity and responsiveness as well as intrusiveness and withdrawal via composite scores,[101]).

Psychobiological Measurements:

Epigenetic Information on the Oxytocin-System and Cortisol/Alpha Amylase in Saliva:

Maternal blood samples are taken to examine the endogenous oxytocin level, gonadal hormones and epigenetic parameters of the oxytocin gene and oxytocin receptor gene. For the endocrine investigation of the stress hormone cortisol painless saliva samples are taken from the infants directly before, immediately after 20 and 30 minutes after the mother-infant interaction using a saliva probe. An elevation of infant stress-reactivity is expected during the interaction, from these elevations the Peak and Recovery be ascertained. The area under the curve is therefore analysed as a reactivity index,[102] as is standard practice,[103].

MRI-tasks:

Reward Task:

The task, (adapted from,[97]), requires participants to perform a spatial working memory task with two levels of cognitive load, differentiated by the number of circles to be remembered. Subjects first see a cue informing them of the potential monetary reward value – high or low. After presentation of the fixation cross, an array of yellow circles (3 or 7 circles), is displayed followed the target, a green circle, that is then presented at any position on the screen. The participants must decide whether this circle is in the same position as one of the circles presented previously. In the rewarded condition, a feedback about the win (followed by the cumulated amount of earned money appears. Correct responses are reinforced by two different amounts of monetary reward that are counterbalanced with the levels of cognitive load. Incorrect responses on rewarded trials result in no monetary gain. While performing the task, participants rate their mood and stress levels a quarter of the trials.

Emotional Go/NoGo:

The participants are presented with positive and negative expressions of unknown babies, unknown adults as well as un-social control stimuli (geometric figures; a circle, a cross, a diamond and a triangle) over three presentation blocks.

The following factors are systematically manipulated: child vs adult and emotionality of facial expression (positive vs negative). In two blocks, the participants receive instructions to respond by pressing a button as fast as possible to all facial expression except the negative (one block babies, one block adults). In two other blocks they are instructed to respond as fast as possible to all except the positive (one block babies, one block adults). In the two non-social blocks the participants should react as fast as possible to all shapes but not to a circle or a diamond,[74].

Eckstein et al NEMO study protocol

Passive Viewing Task:

The participants view previously collected neutral-positive images of partners and their babies in positive and negative affect, with instructions to observe carefully. Unfamiliar men and babies will serve as control stimuli. Viewing images of partners and children leads to the activation of a broad socio-emotional neural network, that is involved with empathy and socio-emotional cognition,[22, 98].

Coding Systems Used in the Study:

Coding Interactive Behaviour:

For the evaluation of the mother-child interaction over all measurement points the Coding Interactive Behaviour System will be used (CIB:[78]). The CIB is a widely used, global rating system for analysing mother-infant-interaction. The system uses multiple codes for the infants, parents and dyadic codes that aggregate into meaningful theoretically-based constructs (e.g., sensitivity, intrusiveness, reciprocity, social engagement, withdrawal). The psychometric characteristics are all well described,[104]. The mother-infant interaction will be coded by blind and reliable coders who are independent of the current study, 10-20% of the videos will be double coded for inter-rater reliability.

Infant Development Diagnostics used in the Study:

Bayley Scales of Infant and Toddler Development-III:

The Bayley Scales of Infant and Toddler Development-III (Bayley-III;[105, 106]) assess the development of infants and toddlers between one and 42 months of age. The test battery covers the domains of cognition, language, motor, social-emotional and adaptive development using I-Q-scaled composite scores. Whereas the first three aspects are assessed by behavioural observation and the latter two utilize questionnaires, with duration ranging between 50 and 90 min,[107]. The Cognitive Scale assesses sensory-motor development, exploration and manipulation, object relatedness, concept formation and memory. The Language Scale is composed of the two subscales receptive and expressive communication. Testing pre-verbal behaviour, vocabulary development, understanding of morphological markers, social referencing and verbal comprehension and pre-verbal communication, vocabulary development and morpho-syntactic development respectively. In addition, the Bayley Scales include a Gross- and Fine-Motor Scale, a Social-Emotional Scale, and an Adaptive Behaviour Scale. This study focuses on the language and cognitive composite scores due to the rather small proposed sample size.

The Bayley-III indices and subscales demonstrate good internal consistency and good split-half-consistency according to the Spearman-Brown formula,[107]. Regarding construct validity, confirmatory factor analysis of the subtests of the Cognitive, Language, and Motor scales supported a three-factor model across all ages. The Bayley-III scales have been normed for German infants and children,[108]. This method is taken standard internationally, particularly in terms of reviewing developmental delays and planning targeted early interventions. The order of the subtests can be adapted to the needs of the child.

Neurofeedback Setup:

The mothers with bonding difficulties will be randomised to receive one of the two following interventions: I) NFB for activation of the ventral striatum or II) neurofeedback for activation of the anterior cingulate cortex (ACC).

The individual masks for extraction of the neurofeedback value are built after the 1st level analyses of the reward task and the emotional go/nogo task submitting the peak voxel coordinates in the right ventral striatum and ACC based on the contrasts [reward > baseline] and [faces nogo > faces go] to build a 12mm-sphere for the striatum ROI and ACC using the marsbar toolbox,[109].

Participants will partake in NFB training over three sessions at intervals of approximately 14 days (refer to Figure 1). At baseline, a high-resolution structural MRI scan and the activation

Eckstein et al NEMO study protocol

pattern based on the infant-like stimuli will be recorded (using a Tim Trio 3T MRI scanner, Siemens, Erlangen, Germany).

Each intervention session will last approximately 60 minutes and will begin with a 10minute preparatory structural MRI scan. A 6minute resting state fMRI scan is then conducted to allow a resting baseline to be established and to prepare the neurofeedback set-up. Afterwards, three rtfMRI NFB runs of 9:29 minutes are conducted. During neurofeedback training positive and neutral pictures of the participants' own child taken from the recorded mother-infant interaction session will be presented together with an on-screen "thermometer" which represents the current intensity of activation in the striatum or ACC and must be upregulated. In each run, six alternating phases of up-regulation (~41 seconds, including a ~10 second initial period without thermometer display) and of rest (observation of a fixation cross, ~41 seconds) will be performed. (See Figure 2 for details). The women are instructed to try and explore different self-chosen strategies (of up-regulation) and find the one that works best for them. Afterwards, they are asked to report which strategy they used and about their subjective success experience. In the first and third scanning session the third run is implemented as a "transfer" block without the visible "thermometer" display,[66, 68, 72].

Functional images are acquired with a Siemens Tim Trio using a T2*weighted echoplanar sequence (TR = 1.64s, TE = 30ms, 30 slices, 3mm slice thickness, FoV = 192mm, flip angle 73°, voxel size 3x3x3 mm, 343 volumes per trainings run, distance factor of 33% and GRAPPA with iPat = 2) and a 32 channel head coil. Control for cardiovascular parameters is conducted using the built-in pulse clip. In-house Matlab software based on SPM12 functions is used to conduct rtfMRI NFB and Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA) is used to present pictures and the feedback signal. At the beginning of each NFB training session, the anatomical image is segmented and normalized to MNI standard space. The inverse deformations of the normalization are then applied to warp the masks of the target regions into subject space.

To correct for movement, each acquired volume is realigned to the first image of the run. Then, volumes with more than 0.5 mm scan-to-scan movements are identified and marked in dummy regressors. Afterwards, the average intensity values from the target region and a cerebrospinal fluid (CSF) mask are extracted and the signal of the target region is corrected for the estimated motion parameters, high-motion dummy regressors, and the CSF signal. For calculation of the feedback signal the ROI intensity value of the last 3 volumes is averaged and compared to the average intensity of the baseline condition. For further technical details regarding the neurofeedback setup please refer to Gerchen et al [110] which uses an identical neurofeedback procedure in the context of alcohol addiction.

[Figure 2: Two Trials of the Neurofeedback Intervention within a Run around here]

Eckstein et al NEMO study protocol

Data Analysis Plan:

Statistical analyses, namely the main comparison of the two groups (mothers with bonding difficulties vs. the control group) and the longitudinal analysis of positive relationships changes after the NFB intervention (interaction behaviour, attachment data, as well as psychophysiological, neuroendocrine and epigenetic markers (see Table 1) will be done using IBM SPSS Statics and R (r-project.org). The MRI data will be analysed with general linear models using statistical parametric mapping with SPM (<https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) implemented (Wellcome Department of Cognitive Neurology, London, UK) in MATLAB (MathWorks, Natick, MA) MATLAB.

For all MRI tasks, all events of the paradigms are modelled by means of general linear model. The relevant contrasts for the go/nogo task are [faces nogo > faces go],[child faces nogo > adult faces nogo] and [negative faces nogo > positive faces nogo]. The relevant contrasts for the reward task are [reward high > reward low], [reward high cognitive load > reward low cognitive load] and [anticipation of reward > baseline]. The relevant contrasts for the passive viewing task are [own infant > unfamiliar child], [positive infant > negative infant], [own partner > unfamiliar man] and [own infant > own partner].

To calculate pre-, post- and follow-up group differences between the intervention and control groups, repeated measures ANOVAs will be calculated, while multi-level models will be used to model changes over the time course.

Eckstein et al NEMO study protocol

Figure Legends:

Figure 1:

Overview of Study Design

Figure 2:

Two Trials of the Neurofeedback Intervention within a Run

For peer review only

Eckstein et al NEMO study protocol

ETHICS AND DISSEMINATION:

Ethics, consent to participate and Dissemination:

Study procedures are in line with the recommendations of the World Medical Association (revised Declaration of Helsinki) and were approved by the Ethics Committee of the Medical Faculty, s-450/2017, Heidelberg University. The study is registered as clinical trial in the German Register for Clinical Trials (DRKS) DRKS00014570. All participants will provide written informed consent after receiving a detailed oral and written explanation of all procedures and can withdraw their consent at any time without negative consequence.

Results will be internationally published and disseminated, to further the discussion on non-pharmacological treatment options in complex mental disorders.

Consent for Publication:

Not applicable.

Availability of Data and Material

For protection of personal rights and due to the sensitivity of the clinical information, raw data will not be available in the public domain. The medical confidentiality and the provisions of the EU-DSG (Data Protection Act) are therefore complied with; the collected medical findings and / or personal information are recorded in the examination centre or stored electronically.

Furthermore, important data for the study are stored in an anonymised format, evaluated and, if necessary, passed on to the necessary persons. Third parties gain no insight into the original data with the database remaining restricted for scientific use only. If results are published, it will not be possible to draw any conclusions to an individual as the confidentiality of personal data remains guaranteed at all time

REFERENCES:

1. Klaus, M., Kennell, J., & Klaus, P., *Bonding*. 1995, New York: Addison-Wesley.
2. Brockington, I., *Postpartum psychiatric disorders*. *Lancet*, 2004. **363**(9405): p. 303-10.
3. Klaus, M.H. and J.H. Kennell, *Parent-infant bonding*. 2. ed. ed. 1982, St. Louis, Mo [u.a.]: Mosby. XIX, 313 S.
4. Maestripieri, D., *Is There Mother–Infant Bonding in Primates?* *Developmental Review*, 2001. **21**(1): p. 93-120.
5. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: psychometric properties and association with postpartum depression*. *Archives of women's mental health*, 2006. **9**(5): p. 265-271.
6. Tietz, A., A.-L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. *Archives of women's mental health*, 2014. **17**(5): p. 433-442.
7. Hornstein, C., E. Hohm, and P. Trautmann-Villalba, *Die postpartale Bindungsstörung: Eine Risikokonstellation für den Infantizid?* *Forensische Psychiatrie, Psychologie, Kriminologie*, 2009. **1**: p. 1-8.
8. Feldman, R., *The adaptive human parental brain: Implications for children's social development*. *Trends in Neurosciences*, 2015. **38**(6): p. 387-399.
9. Moll, J. and J. Schulkin, *Social attachment and aversion in human moral cognition*. *Neuroscience & Biobehavioral Reviews*, 2009. **33**(3): p. 456-465.
10. Moll, J., et al., *A neural signature of affiliative emotion in the human septohypothalamic area*. *Journal of neuroscience*, 2012. **32**(36): p. 12499-12505.
11. Depue, R.A. and J.V. Morrone-Strupinsky, *A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation*. *Behav Brain Sci*, 2005. **28**(3): p. 313-50; discussion 350-95.
12. Strathearn, L., et al., *What's in a smile? Maternal brain responses to infant facial cues*. *Pediatrics*, 2008. **122**(1): p. 40-51.
13. Bakermans-Kranenburg, M.J. and M.H.v. IJzendoorn, *Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting*. *SCAN*, 2008. **3**: p. 128-134.
14. Feldman, R., et al., *Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding*. *Psychol Sci*, 2007. **18**(11): p. 965-70.
15. Reck, C., et al., *The German version of the Postpartum Bonding Instrument: Psychometric properties and association with postpartum depression*. *Archives of Women's Mental Health*, 2006. **9**(5): p. 265-271.
16. Brockington, I., H. Aucamp, and C. Fraser, *Severe disorders of the mother–infant relationship: definitions and frequency*. *Archives of women's mental health*, 2006. **9**(5): p. 243-251.
17. Moehler, E., et al., *Maternal depressive symptoms in the postnatal period are associated with long-term impairment of mother-child bonding*. *Archives of Women's Mental Health*, 2006. **9**(5): p. 273-278.
18. Reck, C., et al., *Perceived parenting stress in the course of postpartum depression: the buffering effect of maternal bonding*. *Arch Womens Ment Health*, 2016. **19**(3): p. 473-82.
19. Brockington, I.F., et al., *A screening questionnaire for mother-infant bonding disorders*. *Archives of Women's Mental Health*, 2001. **3**(4): p. 133-140.
20. Tietz, A., A.L. Zietlow, and C. Reck, *Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour*. *Archives of Women's Mental Health*, 2014. **17**(5): p. 433-42.
21. Hofecker-Fallahpour, M. and A. Riecher-Rössler, *Depression in der frühen Mutterschaft*. *Neurotransmitter Sonderheft*, 2003. **2**: p. 35-39.
22. Laurent, H.K. and J.C. Ablow, *A face a mother could love: depression-related maternal neural responses to infant emotion faces*. *Social neuroscience*, 2013. **8**(3): p. 228-239.
23. Wonch, K.E., et al., *Postpartum depression and brain response to infants: Differential amygdala response and connectivity*. *Social neuroscience*, 2016: p. 1-18.
24. Pawluski, J.L., J.S. Lonstein, and A.S. Fleming, *The Neurobiology of Postpartum Anxiety and Depression*. *Trends in Neurosciences*, 2017. **40**(2): p. 106-120.
25. Reck, C., N. Nonnenmacher, and A.L. Zietlow, *Intergenerational Transmission of Internalizing Behavior: The Role of Maternal Psychopathology, Child Responsiveness and Maternal Attachment Style Insecurity*. *Psychopathology*, 2016. **49**(4): p. 277-284.

Eckstein et al NEMO study protocol

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
26. Zietlow, A.-L., et al., *Maternal Self-confidence Postpartum and at Pre-school Age: The Role of Depression, Anxiety Disorders, Maternal Attachment Insecurity*. *Maternal and Child Health Journal*, 2014. **18**(8): p. 1873-1880.
27. Reck, C., et al., *Interactive coordination of currently depressed inpatient mothers and their infants during the postpartum period*. *Infant Mental Health Journal*, 2011. **32**(5): p. 542-562.
28. Licata, M., et al., *Maternal Emotional Availability and Its Association with Maternal Psychopathology, Attachment Style Insecurity and Theory of Mind*. *Psychopathology*, 2016.
29. Mason, Z.S., R.D. Briggs, and E.J. Silver, *Maternal attachment feelings mediate between maternal reports of depression, infant social-emotional development, and parenting stress*. *Journal of Reproductive and Infant Psychology*, 2011. **29**(4): p. 382-394.
30. Hay, D.F., et al., *Intellectual problems shown by 11-year-old children whose mothers had postnatal depression*. *Journal of Child Psychology and Psychiatry*, 2001. **42**(7): p. 871-889.
31. Meaney, M.J., *Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations*. *Annual review of neuroscience*, 2001. **24**(1): p. 1161-1192.
32. Müller, M., et al., *Effects of Maternal Anxiety Disorders on Infant Self-Comforting Behaviors: The Role of Maternal Bonding, Infant Gender and Age*. *Psychopathology*, 2016. **49**(4): p. 295-304.
33. Dalsant, A., et al., *Maternal bonding in childhood moderates autonomic responses to distress stimuli in adult males*. *Behavioural Brain Research*, 2015. **292**: p. 428-431.
34. Hellhammer, D. and J. Hellhammer, *Stress: the brain-body connection*. 2008: Karger Medical and Scientific Publishers.
35. Brennan, P.A., et al., *Maternal depression and infant cortisol: influences of timing, comorbidity and treatment*. *Journal of Child Psychology and Psychiatry*, 2008. **49**(10): p. 1099-1107.
36. Fernandes, M., et al., *Foetal exposure to maternal depression predicts cortisol responses in infants: findings from rural South India*. *Child: care, health and development*, 2015. **41**(5): p. 677-686.
37. Kaplan, L.A., L. Evans, and C. Monk, *Effects of mothers' prenatal psychiatric status and postnatal caregiving on infant biobehavioral regulation: can prenatal programming be modified?* *Early human development*, 2008. **84**(4): p. 249-256.
38. Champagne, F.A., *Epigenetic mechanisms and the transgenerational effects of maternal care*. *Frontiers in neuroendocrinology*, 2008. **29**(3): p. 386-397.
39. Benoit, D. and K.C. Parker, *Stability and transmission of attachment across three generations*. *Child development*, 1994. **65**(5): p. 1444-1456.
40. Main, M. and E. Hesse, *Parents' unresolved traumatic experiences are related to infant disorganized attachment status: Is frightened and/or frightening parental behavior the linking mechanism?* 1990.
41. Pederson, D.R., et al., *Maternal attachment representations, maternal sensitivity, and the infant-mother attachment relationship*. *Developmental psychology*, 1998. **34**(5): p. 925.
42. Miller, L., et al., *Intergenerational transmission of parental bonding among women*. *Journal of the American Academy of Child & Adolescent Psychiatry*, 1997. **36**(8): p. 1134-1135.
43. Bakermans-Kranenburg, M.J., M.H. van Ijzendoorn, and F. Juffer, *Less is more: Meta-analyses of sensitivity and attachment interventions in early childhood*. *Psychological Bulletin*, 2003. **129**(2): p. 195-215.
44. Kalinauskienė, L., et al., *Supporting insensitive mothers: The Vilnius randomized control trial of video-feedback intervention to promote maternal sensitivity and infant attachment security*. *Child: Care, Health and Development*, 2009. **35**(5): p. 613-623.
45. Bilszta, J.L.C., et al., *Use of video feedback intervention in an inpatient perinatal psychiatric setting to improve maternal parenting*. *Archives of Women's Mental Health*, 2012. **15**(4): p. 249-257.
46. Teti, D.M., et al., *Intervention with African American premature infants: Four-month results of an early intervention program*. *Journal of Early Intervention*, 2009. **31**(2): p. 146-166.
47. Hoffenkamp, H.N., et al., *Effectiveness of hospital-based video interaction guidance on parental interactive behavior, bonding, and stress after preterm birth: A randomized controlled trial*. *Journal of Consulting and Clinical Psychology*, 2015. **83**(2): p. 416-429.
48. Daniel, R. and S. Pollmann, *A universal role of the ventral striatum in reward-based learning: evidence from human studies*. *Neurobiology of learning and memory*, 2014. **114**: p. 90-100.
49. Flagel, S.B., et al., *Individual differences in the propensity to approach signals vs goals promote different adaptations in the dopamine system of rats*. *Psychopharmacology*, 2007. **191**(3): p. 599-607.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
50. Adolphs, R., *The Social Brain: Neural Basis of Social Knowledge*. Annual Review of Psychology, 2009. **60**(1): p. 693-716.
51. Bhanji, J.P. and M.R. Delgado, *The social brain and reward: social information processing in the human striatum*. Wiley Interdisciplinary Reviews: Cognitive Science, 2014. **5**(1): p. 61-73.
52. Montoya, J.L., et al., *Regional brain responses in nulliparous women to emotional infant stimuli*. PLoS One, 2012. **7**(5): p. e36270.
53. Lenzi, D., et al., *Neural basis of maternal communication and emotional expression processing during infant preverbal stage*. Cerebral cortex, 2008. **19**(5): p. 1124-1133.
54. DelDonno, S.R., et al., *Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder*. Psychiatry research, 2015. **230**(1): p. 56-64.
55. Zhang, W.-N., et al., *The neural correlates of reward-related processing in major depressive disorder: a meta-analysis of functional magnetic resonance imaging studies*. Journal of affective disorders, 2013. **151**(2): p. 531-539.
56. Laurent, H.K. and J.C. Ablow, *A cry in the dark: depressed mothers show reduced neural activation to their own infant's cry*. Social Cognitive and Affective Neuroscience, 2012. **7**(2): p. 125-134.
57. Dölen, G., et al., *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin*. Nature, 2013. **501**(7466): p. 179.
58. Ebner, N.C., et al., *Associations between oxytocin receptor gene (OXTR) methylation, plasma oxytocin, and attachment across adulthood*. 2018.
59. King, L., et al., *Perinatal depression and DNA methylation of oxytocin-related genes: a study of mothers and their children*. 2017. **96**: p. 84-94.
60. Galbally, M., et al., *Maternal depression, antidepressant use and placental oxytocin receptor DNA methylation: Findings from the MPEWS study*. 2018. **90**: p. 1-8.
61. Feldman, R., *Oxytocin and social affiliation in humans*. Hormones and Behavior, 2012. **61**(3): p. 380-391.
62. Thibault, R.T., et al., *Neurofeedback with fMRI: A critical systematic review*. NeuroImage, 2017.
63. Sulzer, J., et al., *Real-time fMRI neurofeedback: progress and challenges*. Neuroimage, 2013. **76**: p. 386-399.
64. Moll, J., et al., *Voluntary enhancement of neural signatures of affiliative emotion using FMRI neurofeedback*. PloS one, 2014. **9**(5): p. e97343.
65. Buyukturkoglu, K., et al., *Self-regulation of anterior insula with real-time fMRI and its behavioral effects in obsessive-compulsive disorder: a feasibility study*. PloS one, 2015. **10**(8): p. e0135872.
66. Paret, C., et al., *Alterations of amygdala-prefrontal connectivity with real-time fMRI neurofeedback in BPD patients*. Social cognitive and affective neuroscience, 2016. **11**(6): p. 952-960.
67. Zilverstand, A., et al., *fMRI neurofeedback facilitates anxiety regulation in females with spider phobia*. Frontiers in behavioral neuroscience, 2015. **9**.
68. Kirsch, M., et al., *Real-time functional magnetic resonance imaging neurofeedback can reduce striatal cue-reactivity to alcohol stimuli*. Addiction biology, 2015.
69. Misaki, M., et al., *Real-time fMRI amygdala neurofeedback positive emotional training normalized resting-state functional connectivity in combat veterans with and without PTSD: a connectome-wide investigation*. 2018. **20**: p. 543-555.
70. Ditzen, B. and M. Heinrichs, *Psychobiology of social support: the social dimension of stress buffering*. Restor Neurol Neurosci, 2014. **32**(1): p. 149-62.
71. Cordes, J.S., et al., *Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia*. Frontiers in behavioral neuroscience, 2015. **9**.
72. Young, K.D., et al., *Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder*. PloS one, 2014. **9**(2): p. e88785.
73. Etkin, A., T. Egner, and R. Kalisch, *Emotional processing in anterior cingulate and medial prefrontal cortex*. Trends in Cognitive Sciences, 2011. **15**(2): p. 85-93.
74. Wessa, M., et al., *Fronto-striatal overactivation in euthymic bipolar patients during an emotional go/nogo task*. American Journal of Psychiatry, 2007. **164**(4): p. 638-646.
75. Faul, F., et al., *Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses*. Behavior research methods, 2009. **41**(4): p. 1149-1160.
76. Tronick, E.Z., et al., *The infant's response to entrapment between contradictory messages in face-to-face interaction*. Journal of the American Academy of Child Psychiatry, 1978. **17**(1): p. 1-13.

Eckstein et al NEMO study protocol

- 1
2
3 77. Tronick, E.Z. and J.F. Cohn, *Infant-mother face-to-face interaction: age and gender differences*
4 *in coordination and the occurrence of miscoordination*. Child Development, 1989. **60**(1): p. 85-
5 92.
- 6 78. Feldman, R., *Coding interactive behavior manual*. Unpublished manual, Bar-Ilan University,
7 Israel, 1998.
- 8 79. Reuner, G., & Rosenkranz, J. , *Bayley-III - Bayley Scales of Infant & Toddler Development III.*
9 *Deutsche Version*. . 2015, Frankfurt: Pearson Assessment & Information GmbH.
- 10 80. Margraf, J., et al., *DIPS Open Access: Diagnostic Interview for Mental Disorders. [DIPS Open*
11 *Access: Diagnostisches Interview bei psychischen Störungen.]* 2017, Bochum: Mental Health
12 Research and Treatment Center, Ruhr-Universität Bochum.
- 13 81. Bifulco, A., et al., *Adult attachment style. I: Its relationship to clinical depression*. 2002. **37**(2):
14 p. 50-59.
- 15 82. Bergant, A., et al., *Deutschsprachige Fassung und Validierung der» Edinburgh postnatal*
16 *depression scale* «. DMW-Deutsche Medizinische Wochenschrift, 1998. **123**(03): p. 35-40.
- 17 83. Ehlers, A., J. Margraf, and D. Chambless, *Fragebogen zu körperbezogenen Ängsten,*
18 *Kognitionen und Vermeidung (AKV)*. 2001, Göttingen: Beltz Test.
- 19 84. Lips, H.M. and K. Bloom, *Psychometric Evaluation of a New Scale to Measure Maternal Self-*
20 *Confidence*. 1993: Radford.
- 21 85. Parker, G., H. Tupling, and L.B. Brown, *A Parental Bonding Instrument*. British Journal of
22 Medical Psychology, 1979. **52**(1): p. 1-10.
- 23 86. Schumacher, J., M. Eisemann, and E. Brähler, *Fragebogen zum erinnerten elterlichen*
24 *Erziehungsverhalten*. 2000: Huber.
- 25 87. Ehrenthal, J., et al., *Evaluation der deutschsprachigen Version des bindungsfragebogens*
26 *'Experiences in Close Relationships-Revised' (ECR-RD)*. Psychotherapie Psychosomatik
27 Medizinische Psychologie, 2009. **59**(6): p. 215-223.
- 28 88. Fydrich, T., G. Sommer, and E. Brähler, *Fragebogen zur Sozialen Unterstützung (F-SozU).*
29 *Manual*. Göttingen: Hogrefe.
- 30 89. Zimmermann, J., et al., *The structure and correlates of self-reported DSM-5 maladaptive*
31 *personality traits: Findings from two German-speaking samples*. . Journal of Personality
32 Disorders, 2014. **28**(4).
- 33 90. Klinitzke, G., et al., *[The German Version of the Childhood Trauma Questionnaire (CTQ):*
34 *psychometric characteristics in a representative sample of the general population]*. Psychother
35 Psychosom Med Psychol, 2012. **62**(2): p. 47-51.
- 36 91. Hahlweg, K., *Fragebogen zur Partnerschaftsdiagnostik*. 1996, Göttingen: Hogrefe.
- 37 92. Bodenmann, G., *Dyadisches coping inventar: Testmanual [Dyadic coping inventory: Test*
38 *manual]*. Bern, Switzerland: Huber, 2008.
- 39 93. Tröster, H., *Eltern-Belastungs-Inventar (EBI). Deutsche Version des Parenting Stress Index*
40 *(PSI) von R. R. Abidin*. 2010: Manual Göttingen: Hogrefe.
- 41 94. Bifulco, A., et al., *The Vulnerable Attachment Style Questionnaire (VASQ): an interview-based*
42 *measure of attachment styles that predict depressive disorder*. Psychological Medicine, 2003.
43 **33**(6): p. 1099-1110.
- 44 95. Oldfield, R.C., *The assessment and analysis of handedness: The Edinburgh inventory*.
45 *Neuropsychologia*, 1971. **9**(1): p. 97-113.
- 46 96. Pauli-Pott, U., B. Mertesacker, and D. Beckmann, *Ein Fragebogen zur Erfassung des*
47 *«frühkindlichen Temperaments» im Elternurteil*. Zeitschrift für Kinder- und Jugendpsychiatrie
48 und Psychotherapie, 2003. **31**(2): p. 99-110.
- 49 97. Martin-Soelch, C., et al., *Reduced response to reward in smokers and cannabis users*.
50 *Neuropsychobiology*, 2009. **60**(2): p. 94-103.
- 51 98. Scheele, D., et al., *Oxytocin enhances brain reward system responses in men viewing the face*
52 *of their female partner*. Proceedings of the National Academy of Sciences, 2013. **110**(50): p.
53 20308-20313.
- 54 99. Schwartz, E.P., et al., *Assessing salivary cortisol in studies of child development*. Child
55 *Development*, 1998. **69**(6): p. 1503-1513.
- 56 100. Feldman, R., *Coding interactive behavior manual*. 1998, Unpublished Manual; Bar-Ilan
57 University, Israel.
- 58 101. Feldman, R., S. Masalha, and R. Nadam, *Cultural perspective on work and family: dual-earner*
59 *Israeli-Jewish and Arab families at the transition to parenthood*. J Fam Psychol, 2001. **15**(3): p.
60 492-509.

Eckstein et al NEMO study protocol

102. Pruessner, J.C., et al., *Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change*. Psychoneuroendocrinology, 2003. **28**(7): p. 916-931.
103. Stalder, T., et al., *Assessment of the cortisol awakening response: Summary of the ISPNE expert consensus guidelines*. Psychoneuroendocrinology, 2016. **71**: p. 44.
104. Feldman, R. and S. Masalha, *Parent-child and triadic antecedents of children's social competence: Cultural specificity, shared process*. Developmental Psychology, 2010. **46**(2): p. 455.
105. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Administration Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
106. Bayley, N., *Bayley Scales of Infant and Toddler Development-Third Edition: Technical Manual*. 2006. San Antonio: TX: Harcourt Assessment Google Scholar.
107. Albers, C.A. and A.J. Grieve, *Test review: Bayley, N.(2006). Bayley scales of infant and toddler development-third edition. San Antonio, TX: Harcourt assessment*. Journal of Psychoeducational Assessment, 2007. **25**(2): p. 180-190.
108. Reck, C., et al., *Maternal avoidance, anxiety cognitions and interactive behaviour predicts infant development at 12 months in the context of anxiety disorders in the postpartum period*. Infant Behavior and Development, 2018. **50**: p. 116-131.
109. Brett, M., et al. *Region of interest analysis using an SPM toolbox*. in *8th international conference on functional mapping of the human brain*. 2002. Sendai.
110. Gerchen, M.F., et al., *The SyBil-AA real-time fMRI neurofeedback study: protocol of a single-blind randomized controlled trial in alcohol use disorder*. BMC Psychiatry, 2018. **18**(1): p. 12.

AUTHORS' CONTRIBUTION STATEMENT:

B.D., P.K., A.-L.Z. and M.E. designed the study; M.E. and A.-L.Z. lead the study; S.A.J. collected data; P.K., M.F.G. and M.M.S. established the experimental set-up; S.A.J., A.-L.Z. and ME wrote the manuscript; All authors provided comments on the manuscript.

ACKNOWLEDGEMENTS:

The authors wish to thank Britta Zipser, Ekaterina Schneider, Madgalena Vragovic, Elena Augenstein, Johanna Jübner, Antonia Hüge, Corinna Abdaoui, Nora Nonnenmacher, Nina Schlegel, Josephine Parol, Lydia Oeljeklaus and Hanna-Sophie Lässig for their assistance with conducting the study.

FUNDING STATEMENT:

This work was supported by the Dietmar-Hopp Foundation (September 2017- March 2020). The funding agency had no role in the planning of the study design and will not be involved in data collection, analysis, decision to publish or preparation of the manuscript.


COMPETING INTERESTS STATEMENT:

The authors declare that they have no competing interests.




When Needed:
Neurofeedback-Training
3 Sessions, at intervals of
circa 14 days

BMJ Open



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

T0
8 - 10
Weeks
after
birth



T1
12 - 16
Weeks
after
birth

N1 **N2** **N3**
Week 5




T2
20 - 24
Weeks
after
birth




T3
12
Months
after
birth



Time

-  = Maternal Bloodsample
-  = HRV Mother and Infant
-  = Infant Cortisol Level



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	23
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	23
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	23

1	sponsor contact		
2	information		
3			
4	Roles and	#5c	
5	responsibilities:		
6	sponsor and funder		
7		Role of study sponsor and funders, if any, in study design;	
8		collection, management, analysis, and interpretation of	
9		data; writing of the report; and the decision to submit the	
10		report for publication, including whether they will have	
11		ultimate authority over any of these activities	
12	Roles and	#5d	
13	responsibilities:		
14	committees		
15		Composition, roles, and responsibilities of the coordinating	
16		centre, steering committee, endpoint adjudication	
17		committee, data management team, and other individuals or	
18		groups overseeing the trial, if applicable (see Item 21a for	
19		data monitoring committee)	
20	Background and	#6a	
21	rationale		4-7
22		Description of research question and justification for	
23		undertaking the trial, including summary of relevant studies	
24		(published and unpublished) examining benefits and harms	
25		for each intervention	
26			
27	Background and	#6b	
28	rationale: choice of		7
29	comparators		
30		Explanation for choice of comparators	
31			
32	Objectives	#7	
33			7
34		Specific objectives or hypotheses	
35	Trial design	#8	
36			7
37		Description of trial design including type of trial (eg, parallel	
38		group, crossover, factorial, single group), allocation ratio,	
39		and framework (eg, superiority, equivalence, non-inferiority,	
40		exploratory)	
41			
42	Study setting	#9	
43			14
44		Description of study settings (eg, community clinic,	
45		academic hospital) and list of countries where data will be	
46		collected. Reference to where list of study sites can be	
47		obtained	
48	Eligibility criteria	#10	
49			9
50		Inclusion and exclusion criteria for participants. If applicable,	
51		eligibility criteria for study centres and individuals who will	
52		perform the interventions (eg, surgeons, psychotherapists)	
53			
54	Interventions:	#11a	
55	description		9-10
56			
57		Interventions for each group with sufficient detail to allow	
58		replication, including how and when they will be	
59		administered	
60			

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-14
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	10
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	10
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	9
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	9
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	10
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	15
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	15
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	2
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	23
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

and disclosure of contractual agreements that limit such access for investigators

1			
2			
3			
4	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for
5	trial care		compensation to those who suffer harm from trial
6			participation
7			
8			
9	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial
10	trial results		results to participants, healthcare professionals, the public,
11			and other relevant groups (eg, via publication, reporting in
12			results databases, or other data sharing arrangements),
13			including any publication restrictions
14			
15			
16			
17	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of
18	authorship		professional writers
19			
20			
21	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,
22	reproducible		participant-level dataset, and statistical code
23	research		
24			
25			
26			
27	Informed consent	#32	Model consent form and other related documentation given
28	materials		to participants and authorised surrogates
29			
30			
31	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of
32			biological specimens for genetic or molecular analysis in the
33			current trial and for future use in ancillary studies, if
34			applicable
35			
36			

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60